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Abstract 
Tendon tissue engineering is a field that arose as there became a need for 
alternatives for surgical grafts utilized in injured tendon treatments. This is due to either 
underperforming current technology of off the shelf materials or the fact that there is a 
limited supply of autografts, which is the gold standard for tendon grafting. Tendon 
tissue engineering utilizes all the aspects of the broader tissue engineering field:  an 
appropriate scaffold, a cell source, and stimulation through mechanical and chemical 
means.  This approach adopted herein utilizes the human umbilical vein (HUV) as a 
scaffold and mesenchymal stem cells (MSCs) for a cell source as a tendon construct.  
Previous studies have utilized a custom bioreactor to provide mechanical stimulation to 
this construct in the form of cyclical stretching.  Two week cultures increased the 
mechanical properties, cellularity, and ECM quality of the umbilical vein, improving 
the construct as a tissue engineered tendon. The following studies built upon the 
foundation of the previous research to elucidate the importance of the different 
parameters comprising the mechanical and chemical stimulation. 
The first study presented investigated altering the duration and frequency of the 
mechanical stimulation.  This was done to improve early construct quality by varying 
the two previously mentioned parameters.  By improving early time point culture, the 
future development of the tissue could be greatly improved.  The durations investigated 
included 0.5, 1, and 2 hours/day and the frequencies investigated were 0.5, 1, and 2 
cycles/minute. All dynamic stimulations increased cellular proliferation except for 2 
cycles/min and 2 hours/day.  A 1 cycle/minute frequency resulted in the greatest cellular 
proliferation (170% increase) while the 0.5 hour/day duration was best (203% increase).    
xix 
Extracellular matrix quality had a direct relation to significant increases in cellularity, 
those groups showing the highest matrix deposition and alignment of the matrix.  Gene 
expression indicated cellular activity consistent with remodeling the scaffold to be more 
tendon-like in terms of biglycan and elastin.  In addition, scleraxis, tenascin-C, and 
tenomodulin were upregulated in certain stimulations after at most 7 days, with non-
tendon phenotypes depressed.  The stimulation parameters investigated in this study 
indicated that slower frequencies and shorter durations such as 0.5 cycles/min and 0.5 
hours/day were best for construct quality when short term (up to 1 week) culture are 
employed. 
The second study involved chemical stimulation of the construct.  This study 
aimed to find if an extract of tenocytes can positively affect the development of the 
HUV/MSC construct that also underwent cyclical mechanical stimulation.  This extract 
possesses soluble factors and genetic material from tendons that could potentially 
influence MSC behavior.  By supplementing with tenocytic extract, a synergistic effect 
could be obtained with the aforementioned improved method of mechanical stimulation 
of the construct.  After 14 days of dynamic culture, extract supplemented constructs 
possessed higher cellularity (37% and 150%) and tensile strengths (33% and 45%) 
when compared to non-supplemented MSC or tenocyte groups respectively.  In 
addition, histological images indicated the extract supplemented constructs cultured 
dynamically possessed a dense connective tissue structure similar to native tendon.  
Gene expression profiles indicated that the dynamic construct initially expressed higher 
amounts of collagen type I rather than specific tenocytic markers after 7 days.  
However, after 14 days of dynamic culture, tenocytic marker and tendon development 
xx 
genes such as elastin, scleraxis, and tenomodulin were upregulated, indicating a 
tendency towards a tendon phenotype greater than the non-supplemented group, which 
only received mechanical stimulation.  This indicated that chemical stimulation, in 
addition to the improved upon mechanical stimulation in the previous study, allowed for 
further improvements in the culture compared to either of the two individual stimuli. 
Finally the third study investigated the effects of long term culture (up to 4 
weeks) on the construct.  This was important, due to the fact that the previous two 
studies were limited in culture duration due to the bioreactor and construct design, 
which in turn limited the improvements in the overall construct.  In this study, the 
HUV/MSC construct was modified to be suitable for long term culture within the 
bioreactor by opening the construct into a flat sheet to overcome nutrient transport 
limitations observed in previous studies.  By providing a longer culture time, the 
construct properties could be improved by allowing for more cell and tissue growth.  
Opening the construct initially into a flat sheet increased cell numbers by 15.3 fold 
along with an increased tensile strength of 3.7 ± 0.7 MPa. However, analysis by RT-
PCR showed upregulation of the osteoblastic markers osterix in the MSCs after 21 days 
and osteocalcin after 28 days, along with delayed tenocytic development.  In contrast, 
by culturing the construct in its original cylindrical form for 2 weeks, MSCs are 
protected from the shear forces in their early developmental stages that may have 
increased the osteoblastic tendencies of the MSCs.  After 2 weeks, the HUV is cut open 
into a flat sheet to allow for direct exposure to circulating media.  By doing this, cell 
numbers did increase throughout the culture time but were 71% less than the initially 
open construct.  However, the ultimate tensile strength after 28 days was 5.6 ± 0.7 MPa, 
xxi 
50% higher than the initially open construct.  Gene expression analysis showed earlier 
tenocytic differentiation with the initially closed construct while osterix and osteocalcin 
expression was continually downregulated throughout the 28 days.  
Overall, with the improvements provided by this study, the construct increased 
its ultimate tensile strength by 37% compared to previous studies and the MSCs utilized 
in this study have shown to differentiate towards a tenocytic linage and remodel the  
scaffold with more tendon-like characteristics and an overall higher quality ECM.   
These properties approached some of the properties of native tendons in the body, 
indicating that the HUV/MSC construct in its current form, with further improvements 
can be a viable alternative to current technologies for treating tendon injuries.
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Chapter 1:  Introduction 
Tendon ailments are an increasing prevalent pathology observed within clinical 
settings.  These can be chronic injuries which include tendinosis, tendinitis, and 
tenosynovitis.  These maladies can cause pain, loss of motion, loss of stability, or loss 
of mechanical strength at the injury site.  If left untreated or if these issues reoccur 
frequently, rupture of the tendon can occur. Tendon ruptures can also occur acutely if 
high enough tensile loads are applied to the tendon.  
 The tendon possesses a poor healing capacity due to its sparse cellularity, 
metabolic activity, vascularity, and lymphatic system.1–4  Treatment for chronic issues 
can include rest and rehabilitation.  If a rupture occurs or chronic issues cause enough 
damage, a replacement is needed to maintain the prior tendon’s function.  These 
replacements take on the form of grafts (including allografts and autografts) and 
synthetic materials.5–10  However, these are not without issues, depending on the type of 
replacement, it can cause donor site morbidity, poor integration, loss of mechanical 
integrity, or rejection by the patient’s immune system.11,12  With these issues, an 
alternative to conventional grafts has been desired. 
 Tissue engineering aims to provide graft alternatives through development of 
artificial tissues.  Tissue engineering accomplishes this by creating a construct from any 
or all of the following:  a scaffold, a cell source, and mechanical/chemical stimuli.  
These are usually applied in vitro within custom bioreactors.  By providing some or all 
of these aspects of tissue engineering, tissue growth in vitro can occur and the 
properties of the construct can approach the native tissue if developed properly.  As the 
construct approaches these tissue characteristics, it can be implanted into the patient to 
2 
promote regeneration and integration of surrounding tissue or replace the entire tissue 
entirely.   Tendon tissue engineering, a specific area of tissue engineering, applies the 
broad concepts of tissue engineering to the specific application of tendon replacements.   
 As can be surmised, there are many variables which go into creating a viable 
tissue engineered tendon construct.  These can include scaffold type, cell source, 
seeding densities, the type, timing, and duration of mechanical stimulation, what types 
of chemical stimulation to apply, length of construct culture, and configuration of the 
construct within bioreactors.   
 The work presented in this manuscript investigates many of these variables 
while building upon previous initial studies into an artificial tendon construct created 
out of a human umbilical vein (HUV) and mesenchymal stem cells (MSCs).  Successful 
tissue engineering requires a thorough understanding of the native tissue, therefore 
chapter 2 will investigate the tendon biology, physical properties, and pathologies.  
Chapter 3 will describe techniques used for tendon tissue engineering.  Chapter 4 will 
investigate how changing the parameters of mechanical stretching affects initial culture 
of the tendon construct.  By improving the initial construct cultures, future culture times 
can be more beneficial also, and the overall result creates a higher quality tissue-
engineered construct. As a supplement to mechanical stimulation, chapter 5 will 
describe the use of tenocytic extract as a chemical stimuli for tendon development.  By 
combining a mechanical and chemical stimulus together, beneficial effect from both  
stimuli at the same time can occur, resulting in improved properties compared than the 
stimuli alone.  Chapter 6 will then describe the ability of the existing system to culture 
for periods of up to 4 weeks, whereas, only 2 weeks of culture had been previously 
3 
allowed Long term culture allows for greater improvements in cellularity, ECM creation 
and remodeling, mechanical properties, and differentiation into a tenocytic lineage.  The 
sum of these three chapters will result in a construct that has been not only improved 
from previous studies, but allow for future development into a viable and improved 
upon alternative to current surgical grafts for treating tendon injuries. Finally chapter 7 
will provide some conclusions for the entire body of work along with some future 
directions the project can take.  By combining previous research with this specific 
system, along with the current manuscript, and the suggested future directions, a viable 
graft replacement can become closer to reality. 
4 
Chapter 2:  Tendon Properties and Pathologies 
2.1 Introduction 
 Tendons are primarily collagenous tissues that are responsible for connecting 
bone and muscle and transmitting forces between the two.  Tendons can vary in shape 
and size depending on the location in the body and amount of forces being transferred.  
These shapes range from flat to ribbon to cylindrical.13  To illustrate the complete 
muscle/tendon/bone unit, the Achilles tendon, the strongest and largest tendon in the 
body, is pictured in figure 2.1. 
 
Figure 2.1:  Image of the Achilles Tendon connecting the muscles of the calf to the 
calcaneus bone in a rat.  
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 The tendon is designed to transmit and withstand high amounts of force.  
However, with continuous, long term overuse or a high, instantaneous, and unfamiliar 
stress, injury can occur, which may eventually lead to a tendon rupture which requires 
surgical treatment.15–17 With chronic injuries, inflammation may occur around the 
injured site (tendinitis) or the tendon may suffer microtears within the matrix 
(tendinosis).17  Although these pathologies are commonly associated with athletes and 
repetitive, high stress activities, they can also occur with common, day to day 
activities.17,18   One hypothesis for recent increases in tendon injuries in the general 
population is due to the increase in sedentary lifestyle for industrialized countries, 
which leads to weaker tendons when actually in use.19  A different population, athletes, 
which are more prone to tendon injuries, experienced 232,000 injuries in 2002.20 On 
average, days of work lost due to tendon injuries averaged 16 days per year.21  When 
considering only tendon ruptures, time lost from work can depend on treatment.  Time 
lost from surgery averaged 13 weeks, while patients who opted for non-surgical 
treatment still missed  9 weeks of work recovering from a tendon rupture.22  Taken 
together, tendon injuries cause a disruption in day to day life and advances in treatment 
of these pathologies can be extremely beneficial. 
 This chapter will first describe the tendon structure, composition, and 
organization, along with its mechanical properties.  It will then conclude with a 
description of tendon pathologies and current clinical treatments for both chronic and 
acute injuries. 
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2.2 Tendon Organization 
Tendons are soft connective tissues that connect and transmit forces from the 
muscle to the bone.14  They are composed primarily of collagen along with other 
extracellular matrix (ECM) molecules and cells that will be discussed in sections 2.3 
and 2.4.23 
  The tendon can be thought of as many well organized subunits combined 
together to function as a cohesive tissue.  The smallest unit of the tendon is the collagen 
molecule, which in itself is comprised of smaller subunits.  It is a triple helical protein 
that has a diameter of about 1.5 nm, a functional length of 300 nm, and is comprised of 
two subunits, two 1 chains and one 2 chain.25  These chains follow a Gly-X-Y amino 
acid pattern where every third residue is glycine and also are rich in proline.26  These 
molecules are then arranged into fibrils, which are comprised of overlapping collagen 
molecules with a 64 nm periodicity.27  These fibrils are not linear, but are crimped, 
which is a result of a periodic triangular arrangement.28  
 The resulting fibrils are then organized into fibers, which are further organized 
into bundles called fascicles.  Within the fascicles reside the cells of the tendon, of 
which types will be discussed later.29  These fascicles also show a crimp pattern, due to 
the amplification of the crimping present in the fibrils.28  Both bundles of collagen 
fibers and fibrils are wrapped together by a dense connective tissue called the 
endotendon.30  Bundles of fascicles are grouped together by the epitenon and form the 
macrostructure of the tendon, this tissue is similar in form and function to the 
endotenon.30  Finally, there is another outer layer of the tendon, the paratenon.  This 
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consists of both type I and type III collagens along with elastin and synovial cells.  This 
layer provides lubrication and protection from surrounding tissues.24,30 
The junctions of the tendon to the bone and muscle have slightly different 
anatomies.  The myotendinous junction is a region where the muscle merges into the 
tendon, creating a relatively smooth transition.  Muscle cell membrane and actin 
filaments form finger like appendages that extend into the tendon as shown in figure 
2.2.31  These appendages are responsible for transmitting force from the muscle to the 
tendon.  They are also very stable, as many of the muscle and tendon ruptures around 
this area occur near the transition zone, but not actually within it.32 
 
Figure 2.2:  Schematic of the myotendinous junction.  Muscle processes can be 
seen protruding into the tendon to form a connection of the two tissues.  
 
The osteotendinous junction or enthesis has a length of nearly 1 mm and serves 
as a transition from the soft connective tissue of the tendon to the calcified bone.33 
There are 4 zones within the enthesis:  the tendon, non-mineralized fibrocartilage, 
mineralized fibrocartilage, and then the bone.13 The enthesis can occur either directly 
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where the tendon directly contacts the bone at a right angle or whether it has an indirect 
insertion where it blends with the periosteum of the bone.33  
 Internal vascularization of the tendon is typically formed longitudinally through 
the tendon around the fibers in the endotenon.35,36  The origination of these vessels 
occur in three locations:  the muscle/tendon junction, the bone/tendon junction, and 
through the paratenon.37,38  However, even with all of these supplies, the vascularization 
of the tendon is poor, which helps contribute to the poor healing capacity of the 
tendon.39 
 
2.3 Tendon ECM Composition 
Tendon ECM is comprised mostly of collagen and water.  Water is about 60- 
80% of the wet weight of the tendon.40  Furthermore, collagen type I composes nearly 
80%-95% of the dry weight of the tendon.24 Collagen type III, found mainly in the 
epitenon and endotendon, and collagen type V, found in the core of collagen type I 
fibrils, are the other collagen types found in substantial amount (nearly 5% total).30,41,42  
Collagen type III and type V are both thought to regulate fibril diameter within the 
tendon41,43 There are also small amounts of collagen types II, VI, IX, X, and XI present 
mostly at bone insertion sites to improve the bone/tendon connection strength.41,44   
 Other than collagen, there are other proteins and ECM molecules present that 
provide stability, elasticity, lubrication, and maturation of development to the tendon.  
Elastic fibers consist of 1-2% of the tendon dry weight.45  These fibers are thought to 
allow for recovery of the collagen fibers after the load on the tendon has stopped, 
providing elasticity.46  Besides the elastic fibers, there is the ground substance, which 
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includes proteoglycans, glycosaminoglycans (GAGs), and glycoproteins.  Some of these 
include biglycan and decorin, proteoglycans which help regulate the formation of 
collagen fibrils in development and is also though to assist in early and late stage 
healing.47,48  Tenascin-C, a glycoprotein is often found in developing or healing 
tendons, although not as often in normal tendons.49  Tenomodulin, another glycoprotein, 
is highly expressed by tendon cells, and is involved in the recruitment of tenocytes, 
maturation of collagen fibrils, and also a marker of tenocytic differentiation of stem 
cells.50,51  GAGs such as chondroitin and dermatan sulfate are present in the tendon, and 
are thought to potentially assist in mechanical integrity of the tendon.52 
 The previous description was the composition of the main portion of the tendon, 
and although the junctions where the tendon meets the bone and muscle are similar, 
they also have some differences in makeup.  For example, tendons near the 
myotendinous junction sre still composed mainly of collagen type I but also possess 
more collagen type VI and tenascin C compared to the main body of the tendon.31  The 
osteotendinous junction, which is comprised of the four zones, has a spatial variance in 
composition.  The tendon at the junction contains mostly collagen type I and decorin.  
While the fibrocartilage contains collagen types II and III, aggrecan, and decorin.  The 
third mineralized cartilage zone is made up of collagen type II and X, and aggrecan.  
Finally, the bone portion of the junction is composed mostly of mineralized matrix.53 
 
2.4 Cells of the Tendon 
Cells of  a developed tendon are comprised of 90-95% tenocytes.13  The 
remaining cells are related to the neighboring tissues at the junctions of the tendon, 
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synovial cells, and vascular-related cells.30   The tenocyte arise from the tenoblast, 
which is the immature terminal cell of the tendon found mainly during devleopment.54  
These cells are metabolically more active than tenocytes and as they mature, they lose 
much of their activity and become tenocytes.54 Tenocytes are elongated and also 
possess elongated nuclei, often spindle shaped.  They are anywhere from 20-70 m long 
and 8-20 m wide.55,56  These cells are more dense in developing and young tendons, 
while they decrease in amount as the tendon matures.13,55  Tendons of a newborn can 
have as many as 200,000 cells/mm3  and decrease to 50,000 cells/mm3 as an adult.57  As 
they mature, they develop longer cell processes to maintain cell-to-cell contact, due to 
their decreasing number.30 
Tenocytes express genes that are related to proteins found throughout the ECM 
of the tendon and produce the related molecules. This infers that these cells are at least 
responsible for normal tendon maintenance and also play a part in tendon regeneration 
and healing.30 These genes include, but are not limited to:  collagen type I, collagen type 
III, collagen type V, decorin, biglycan, elastin, scleraxis, tenascin C, tenomodulin, and 
growth factors such as bone morphogenic protein (BMP) 4 and isoforms of 
transforming growth factor beta (TGF-).30,58–64  As will be discussed later, these genes 
can therefore be utilized to signify differentiation of MSCs into tenocytes.   
The metabolism of tenocytes relies on both aerobic and anaerobic pathways, 
however, as tenocytes age, glycolysis and anaerobic energy production is preferred.65,66  
Matrix metabolism follows a similar trend, where matrix production is high in early 
development and slows in the mature tendon, including collagen turnover.30  However, 
this slow metabolism also inhibits healing of injured tendons.1,67 
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Within the past few years, another niche of cells within the tendon has been 
discovered.  The cells, tendon derived stem cells (TDSCs), are found within the tendon, 
are multi-potent and possess similar characteristics to MSCs.68–71  However, these cells 
actually possessed greater proliferation, higher differentiation potency, and possessed 
more BMP receptors, indicating a different phenotype than MSCs.72  Even then, it is 
thought that both of these cell lines originated from the same precursor cells during 
development.  These cells are found throughout the tendon, as they have been isolated 
from the vascular-rich paratenon and also between collagen fibrils.72  These cells are 
also thought to play a role in tendon healing, as they were found at tendon wound sites 
after initial healing began with traditional MSCs.73  Their function and fate are most 
likely determined by numerous biological factors, physiological factors, tenocyte 
communication, and mechanical stimulation.74 
 
2.5 Mechanotransduction of Tendon Cells 
Tendons are a highly mechanical tissue, transferring forces from muscle to 
tendon.  Previously, cell processes were described as a way for tendon cells to 
communicate.  In addition, tenocytes also utilize gap junctions, especially in response to 
mechanical loading of the tendon.75  The process of converting mechanical stimulation 
to a biochemical response is called mechanotransduction. 
The process of mechanotransduction is still not fully understood, applies also to 
tendon cells.44,76  Studies involving several cell types have shown that 
mechanotransduction can include integrins, ion channels, focal adhesions, and growth 
factors and their receptors.77  This in turn, activates the cell signaling cascade, which 
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can involve any of the Rho-dependent kinase, nuclear factor kappa B (NF), mitogen-
activated protein kinase (MAPK), and protein kinase C (PKC) pathways.77,78  These 
pathways then affect gene transcription and expression.  A general schematic of these 
processes is shown in figure 2.3.   
 
Figure 2.3:  Diagram showing mechanotransduction in response to mechanical 
loading.  
 
The gene expression changes due to mechanical stress on the tendon cell is a 
complex cascade dependent on the nature of the stress in many cases.  Positive 
mechanical stress can increase collagen production of tenocytes, proliferation rates, and 
expression of growth factors such as TGF-, platelet-derived growth factor (PDGF), 
and fibroblast growth factor 2 (FGF-2) .79–81  In addition, stretching also promotes the 
expression of vascular endothelial growth factor (VEGF) within tenocytes.82  This 
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factor promotes vascularization, allowing for increased blood flow and healing at an 
injured site.83 
However, mechanical loading can also have drawbacks if the stress is large 
enough.  After 12% stress it has been shown that tenocytes increase the production of 
cyclooxygenase 1 and 2, along with prostaglandin E2, which are related to 
inflammation of the tendon.84  This is also true for other inflammatory cytokines.85–88  It 
has also been shown that these lead to increased expression of matrix 
metalloproteinases (MMPs) which can be responsible for breakdown of the tendon 
ECM if expressed in high levels.85,89  In addition increasing mechanical strains of up to 
9% have shown to increase activation of the c-Jun N-terminal kinase pathway, which 
when persistently activated, can lead to apoptosis.90 
As tendon stem cells were discovered relatively recently, little has been known 
about their response to mechanical stimulation in vivo.  However, in vitro, at low strains 
(4%), mechanical stimulation induces the tendon stem cells to become tenocytes, while 
larger strains induced differentiation into osteogenic, chondrogenic, and adipogenic 
lineages.91,92 This may provide insight into part of the reason why controlled 
rehabilitation encourages tendon repair, while high mechanical loads and subsequent 
tendon injuries cause irregular tendon tissue formation, such as calcification and lipid 
formation.3,91,93 
 
2.5 Mechanical Properties of the Tendon 
Since various tendons throughout the body have different functions and 
mechanical loads to transfer, the mechanical properties of the different tendons can vary 
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significantly.  Table 2.1 gives mechanical properties for some of the tendons in the 
body.  
 Ultimate 
Tensile 
Strength (MPa) 
Young’s 
Modulus 
(MPa) 
Strain at 
Maximum 
Stress (%) 
Achilles 819 ± 208 870 ± 200 8.8 ± 1.9 
Patellar (29-50 
years old) 
64.7 ± 15.0 660 ± 266 14 ± 6 
Patellar (64-93 
years old) 
53.6 ± 10.0 504 ± 222 15 ± 5 
Anterior 
Supraspinatus 
(Rotator Cuff) 
16.5 ± 7.1 165 ± 20 N/A 
Middle 
Supraspinatus 
(Rotator Cuff) 
6.0 ± 26 70 ± 20 N/A 
Posterior 
Supraspinatus 
(Rotator Cuff) 
4.1 ± 1.3 40 ± 15 N/A 
Table 2-1:  Mechanical properties for selected tendons throughout the body.94–97 
 
 Also as seen in the table, there is a difference in mechanical properties of the 
tendon due to age.  A healthy adult patellar tendon had superior mechanical properties 
compared to an older patient.96  This is also seen in newborns, where the tendons of a 
newborn, which is not finished developing, are weaker than developed tendons.98  
Finally, there can also be a difference within the tendon, when it is heterogeneous, as is 
seen in the rotator cuff tendon.97  Even though the ultimate tensile strengths of the 
various tendons can approach nearly 1 GPa, actual physiological forces are much lower.  
For example, the strongest tendon in the body, the Achilles tendon, will experience a 53 
MPa stress during human running, only 1/15th the ultimate tensile strength of the 
Achilles tendon.94,99 
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 Between the previously mentioned crimp of the collagen fibers, its water 
content, and other proteins found in the ECM of the tendon, tendons exhibit viscoelastic 
behaivior.100  Viscoelastic materials have a transient relationship between stress and 
strain, shown in figure 2.4.  When a viscoelastic material is exposed to a constant stress 
for certain amount of time, creep will occur.  This phenomenon is observed when the 
strain of the material increases to a certain threshold to accommodate the applied stress 
by rearranging its individual subunits, in this case, fibrils and fascicles of the tendon.102  
When the stress is unloaded, the material recovers to its original configuration.  On the 
other hand, when a constant strain is applied, the viscoelastic material undergoes stress 
relaxation.  When the strain is initially applied, the stress reaches a maximum and then 
decreases until the strain is released.  Afterwards, the viscoelastic material will 
recover.102  Another property of viscoelastic materials is hysteresis.  This is represented 
by a loop in the stress-strain curve when a material is loaded and relaxed.  This loop 
represented energy that is dissipated by the viscoelastic material during loading and 
unloading, usually in the form of heat.103  This energy is wasted energy when 
transmitting forces from the muscle to the bone.  Finally, because the tendon is 
viscoelastic, its stiffness depends on the velocity of the stretching applied, with it 
becoming more stiff at higher velocities.104  Therefore, a higher amount of force will be 
required to rupture a tendon with a fast change in mechanical load, protecting the 
tendon.  Summarized, low strain rates allow for the tendon to absorb more energy but 
transfer less mechanical load, while high strain rates allow the tendon to become stiff 
and transfer higher mechanical loads with less deformation.13 
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Figure 2.4:  Stress-strain transient relationships for viscoelastic material.  Creep is 
demonstrated on the left while stress relaxation is shown on the right.  
 
 Figure 2.5 shows a typical stress-strain curve of the tendon.  It consists of four 
regions.  The first region is the toe region.  Generally, up until about 2% strain, the 
crimp within the fibers straighten out with initial elongation.44  If there is a sudden, 
large initial loading, this protects the tendon from early failure.105  The linear region 
occurs until nearly 4% strain. This is where fibers are still being elongated, and fully 
lose their crimp.44  Up until 4%, any elongation and deformation can be fully recovered 
by the tendon.13,106 After this point, failure begins to occur.  However, most normal 
physiological forces only exert up to a 4% strain on the tendon, allowing for recovery in 
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most situations.13,42,106 If enough load is applied, microscopic failure or tears within 
collagen fibrils appear first, up to 8-10% strain.44  This area is where many of the 
tendinopathies can occur, and will be discussed in the next section.  After about 10% 
strain, rupture, or macro-failure of the tendon occurs, and at this point, surgical 
intervention is usually required.13,44   
 
Figure 2.5:  Stress strain curve of a tendon, indicating tendon fiber pattern for 
each of the four regions:  toe, linear, microscopic failure, and macroscopic failure.  
 
2.6 Tendon Pathologies 
Tendons as discussed previously possess poor healing capacity.  This is due to 
sparse cellularity, low vascularity, and low metabolism in normal tendons.1,2,4,13  For 
example, tendons have about a 1/3 of the blood supply of muscles, that are considered 
highly vascularized tissues.107  Therefore, if not treated properly, even common tendon 
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injuries can lead into more serious tendon pathologies such as rupture, which in most 
cases requires surgery and a potential need for a graft.  As was discussed in the 
introduction, the statistics point to many work hours lost to tendon injuries and for the 
patient, a loss of quality of life due to acute and chronic tendinopathies is a common 
outcome.  This section will cover the various typical tendon pathologies, their 
symptoms, causes, and common treatment methods.   
 
2.6.1 Tendinitis and Paratendinitis 
Tendinitis is the occurrence of inflammation within the tendon.  Its symptoms 
include pain and tenderness, which can increase at night or with activity.108  Other 
symptoms related to inflammation may occur such as warmth and swelling.13  It is often 
caused by overuse and repeated injury to the tendon.109  It includes common injuries 
such as tennis elbow and jumper’s knee. 
Often the inflammation phase lasts for 2-5 days and then remodeling occurs.13  
This involves recruitment of tendon cells and remodeling of the ECM of the tendon at 
the injured site.  However, this ECM is still immature and disorganized, and without 
proper protection and rest, reinjury can occur fairly easily, leading to a more chronic 
injury.110  As such, rest and support is important in clinical treatment of the injury.  If 
rest and braces are not enough, non-steroidal anti-inflammatory drugs (NSAIDs) and 
corticosteroids can help alleviate symptoms and recovery.111 
Paratendinitis is similar to tendonitis, but is limited in location to the outer layer 
of the tendon, the paratenon.13  As such, the symptoms and treatments for paratendinitis 
are the same as for general tendinitis.   
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2.6.2 Tendinosis 
Tendinosis is the occurrence of microscopic tears within the collagen 
fibrils.13,112,113  These tears are accompanied with an increase in cellular density and 
there is little to no inflammation present.112  The tendon itself when healthy is glistening 
white, but is described as dull and brown when inflicted with tendinosis.114  Tendinosis 
is separate from tendinitis, but tendinitis may accompany tendinosis.13 
On an ECM level, tendinosis often is accompanied by an increase of collagen 
type III fibers.  These fibers are immature and disorganized, which leads to a weaker 
tendon.115  Along with this, the existing collagen type I is often denatured or 
damaged.116  Furthermore, MMP activity is higher along with low pentosidine levels 
(signifying new matrix) indicating that remodeling and recovery is occurring at the 
injury site.116  In addition, ground substance of the tendon is increased. 113,117  Ground 
substance gives an appearance of disorganized matrix, but is also found to assist in the 
assembly of mature collagen, potentially providing a benefit to the recovering 
tendon.118,119 
 As long as tendinosis is not severe enough to warrant surgical intervention, 
treatment suggested includes rest, rehabilitation, supports, and proper nutrition when 
applicable.115  Oftentimes physicians will misdiagnose or treat tendinosis as tendinitis 
and treat with NSAIDs and other anti-inflammatory treatments.114  However, as there is 
no inflammation occurring directly with tendinosis, these are not effective in the 
recovery process.  Whereas tendonitis recovery can occur within a couple of weeks as 
long as it is not chronic, tendinosis has a longer recovery time.  This recovery time can 
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range from 6 weeks to 9 months depending on severity and whether it is acute or 
chronic.114,120   
 
2.6.3 Tendon Rupture 
Many tendon ruptures occur spontaneously when the tendon experiences a large, 
abnormal force through a physical activity.13  However, chronic and overuse injuries 
can also exacerbate and cause tendon ruptures.66,121  There are two types of tears:  
partial tears where the muscle/tendon/bone unit are still connected with significant 
macrotearing of the tendon, or a complete rupture where there is separation somewhere 
within the muscle/tendon/bone unit.121 
Ruptured tendons display less collagen content than normal tendons along with 
reduced mechanical properties.122  Similarly to tendinosis, collagen type III content was 
increased compared to the normal tendon, as part of the healing process.  However, this 
also decreases the tensile strength and collagen quality of the tendon.123  Also MMP 
activity is higher at the rupture site, possibly leading to further degradation after the 
initial injury, further reducing mechanical integrity.124,125  It is thought that these MMPs 
are initially utilized to repair and turnover damaged collagen, however, regulation may 
be compromised with chronic injury or additional strain on the injury site.125 
Surgical treatment of both partial and complete ruptures is the most common 
form of treatment.13,121  However, recently more conservative treatment methods such 
as rest and rehabilitation has been used in some cases with success, especially with 
patients that are poor surgical candidates such as the elderly.126–130  However, rerupture 
rates are four times greater with non-surgery than surgical treatment of the rupture.127   
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If the rupture is small enough, the gap may be sutured together, utilizing techniques 
such as the modified Kessler suture.127  If the defect is large enough (2 cm) a graft may 
be needed.131  Surgeons have many different graft options such as:  xenografts, 
allografts, autografts, and synthetic materials.  Table 2.2 gives a listing of some of the 
common grafts used in tendon treatment.  Xenografts are often times porcine in nature.  
They and allografts are mostly decellularized to reduce the chance of an immune 
reaction.132,133  Autografts come from locations that have redundant function and good 
healing capacity, such as the semitendinosus tendon connecting the hamstring to the 
back of the knee.149  Finally, synthetic grafts are often polymeric in nature, possessing 
mechanical properties and degradation rates to support regeneration of tissue while 
providing adequate support.140  However, they are not without issue, as these grafts can 
also have complications.  Xenografts and allografts can still elicit an immune 
response.12,150  Autografts have the complication of donor site morbidity along with a 
second surgical site and accompanying pain.151 Synthetic grafts can cause poor healing 
of regenerated tissue and mechanical properties can be degraded with long-term 
usage.11,152 
Surgery currently provides the best chance of full recovery in tendon rupture as 
long as there is not complications.22,153  Rerupture rates for surgical treatment of 
Achilles tendon ruptures was 1.54% while rates for non-surgery treatments were 
17.7%.22  However, even with successful surgical intervention of a rupture, some 
tendon functionality may be missing up to 2 years after treatment.154 Additionally, even 
though surgical treatment may give the best odds for recovery, rerupture can still  
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occur.154  Ideally, as will be discussed in chapter 3, a tissue engineered tendon would be 
able to reduce or eliminate this time of reduced function.   
2.7 Conclusions 
Tendons are relatively inert soft tissues that transmit mechanical forces from the 
muscle to the bone. They are comprised mostly of collagen type I fibrils along with 
small amounts of other proteins that provide support, elasticity, and hydration.  Normal 
tendons are sparsely cellularized and its cells have low metabolism.   The tendon’s 
unique mechanical properties are due to its viscoelastic nature.  This allows it to adjust 
the type and rate of mechanical load and recover fully.  Since tendons are poorly 
vascularized and have low cellularity with low cell metabolism, healing capacity is poor 
compared to other tissues of the body.  This can result in chronic or acute 
tendinopathies.  These tendinopathies can include tendinitis (inflammation), tendinosis 
(microtears), or rupture.  In some cases, rest, rehabilitation, and medication is all that is 
needed for recovery.  However, in severe enough cases, such as rupture, surgery is 
needed to either clean out damaged tissue, suture a small gap, less than critical defect 
size of the tendon, or apply a graft to supplement the native tissue.  Grafts can come 
from xenografts, allografts, autografts, or synthetic grafts.  All of these have benefits 
and drawbacks, some or all of which could be remedied with a tissue engineered 
construct.  Chapter 3 will discuss the current state of tendon tissue engineering. 
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Chapter 3:  Tendon Tissue Engineering 
3.1 Introduction 
Tissue engineering is the application of engineering and biology among other 
fields to create an artificial neotissue that can be utilized as a graft in vivo to either 
replace or assist the regeneration of injured native tissue.155  The field arose as a need 
for alternatives for grafts during surgical treatment of injuries developed.  This could be 
due to the lack of availability of grafts, inadequate healing, or immune responses among 
other reasons.156,157  A successful tissue engineered construct will support cell growth, 
tissue formation, and when implanted, not elicit an immune response and integrate with 
natural tissue.24,155  The following sections will discuss each aspect of tendon tissue 
engineering in more detail and their importance to the overall construct.  
 
3.2 Functional Tendon Tissue Engineering 
Functional tissue engineering refers to the creation of an artificial neotissue that 
resembles or has the same biological and biomechanical properties of the native tissue it 
is replacing155  For this to occur, most or all of these three aspects should be utilized:  a 
biocompatible scaffold, a cell source, and stimulation via biochemical or mechanical 
means either in vitro or in vivo, or both. 24,46,155,158–162  The following sections will 
discuss the important aspects of each and how to relate to each other to form a 
functional tendon tissue engineered construct.  
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3.2.1 Scaffolds 
An initial requirement for a scaffold utilized in tendon tissue engineering is the 
ability to initially support (or be modified to allow) cell attachment, allow for nutrient 
transport within the tissue, and allow for integration of new tissue both in vitro and in 
vivo.158,163,164  This scaffold should also ideally have mechanical properties that 
approach the native tissue’s.164   In addition the scaffold needs to not elicit an immune 
response when implanted.165  Furthermore, the degradation rate must be tailored to 
support tissue growth initially while providing sufficient mechanical support.164  
Degradation rates can depend on structure, molecular weight, morphology, porosity, 
and where it is implanted.166  When degrading, the materials must be bioresorbable so 
that the degradation products are eliminated through natural means within the body.163 
Natural material based scaffolds consist mostly of collagen type I based gels for 
tendon tissue engineering.167–170  This is a popular choice as collagen type I composes a 
significant portion of the dry weight of tendons.11 These gels seeded with MSCs have 
shown increased healing and function in vivo in rabbit Achilles tendon injuries.167  
However, these collagen gels do not replicate the aligned fibril structure of the tendon 
and their mechanical strength is usually lacking compared to mature tendons.11  To 
remedy the mechanical strength issues of collagen gels while maintaining some of the 
natural material characteristics, some researchers have created hybrid collagen gels with 
synthetic polymers or silk.171–173  Small intestine submucosa (SIS), chitosan, alginate, 
and hyaluronic acid have also been used as natural materials in tendon tissue 
engineering scaffolds, but to a much lesser extent than collagen hydrogels.174–177   
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The natural material utilized in the research presented in this dissertation is the 
HUV.  The vein is obtained from umbilical cords which are otherwise discarded after 
birth.  It has many of the benefits of being a natural material like collagen, however, it 
also possesses a higher initial mechanical strength than collagen hydrogels.178–182 In 
fact, the decellularized HUV is only an order of magnitude weaker than some of the 
tendons in the body.13 The HUV has been utilized in various tissue engineering 
strategies from blood vessels to the vocal fold.183,184  The HUV and its other umbilical 
vessel, the human umbilical artery (HUA) possess similar mechanical strengths:  1.47  
1.08 MPa and 1.37 0.80 MPa respectively for the HUV and HUA.185,186  In addition, it 
has also been utilized in previous studies for tendon tissue engineering by Abousleiman, 
et al upon which these studies were based.178–180  The HUV supported cell growth and 
ECM deposition, and when cyclically stretched, the ECM became aligned and MSCs 
became more tenocytic-like in appearance.178,179  Furthermore, the mechanical strength 
of the HUV was increased by 3 fold to 4.1 ± 0.5 MPa when supplemented with MSCs 
and stimulated for 2 weeks.180 
Another benefit to the HUV is its performance and immunological 
characteristics to xenografts, or tissues from another species.  To create a high quality 
graft, cellular incorporation into the scaffold must be at high levels. It has been shown 
that human fibroblasts infiltrate more efficiently and further on human dermis allografts 
compared to porcine dermis xenografts.187 In terms of use in clinical settings, xenografts 
have shown to cause local and systemic immune responses, even after the typical 
surgical recovery time.188–190  This has also been seen in tendon specific xenografts 
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through both non-specific and specific (potential allergic reaction) immune 
responses.191–193 
Ideally, a decellularized healthy tendon (ether from the patient or another donor) 
would be one of the best scaffolds for a tissue engineered tendon replacement as it 
would have tendon specific biomolecules and possess a mechanical strength near the 
native tissue.  If decellularized completely, immune responses should be limited.166 
However, the supply of such a scaffold is scarce and still carries the chance for disease 
transmission.194  In addition, the decellularization process can negatively affect the 
structure and mechanical strength of the tendon and remove some of the beneficial 
biomolecules.195  There have been some studies utilizing the decellularized tendon as a 
scaffold in the literature.196–198  Decellularized tendons have shown the ability to 
support reseeding of cells along with increased ECM deposition and increased 
mechanical strength.198  However, histology has shown that the scaffold doesn’t 
facilitate easy migration and incorporation of the cells as they primarily reside on the 
surface of the scaffold.196,197 
One of the biggest drawbacks of natural materials is their initial mechanical 
strength.  Synthetic polymers tend to have higher mechanical strength, but are 
accompanied by poor cell attachment (due to their hydrophobic nature) and sometimes 
immune responses (in some cases).163,164,199   Synthetic polymers used in tendon tissue 
engineering include but are not limited to: polyglycolic acid (PGA),  polylactic acid 
(PDLA and PLLA), its l-lactide form poly-l-lactic acid (PLLA), poly(lactic-co-glycolic) 
acid (PLGA), polycaprolactone (PCL), and polydioxanone.131,200–208  In the literature, 
PLGA is most commonly used among these options.131,200–202,205  A reason for this is 
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due to its ability to be tuned based on ratios of PLA and PGA.  Based on the ratios, 
properties such as degradation rates and mechanical strength can be changed based on 
need.209,210  Braided PLGA has been utilized due to its high tensile strengths compared 
to other PLGA preparations.211  However, even though cells did attach on the surface of 
braided scaffolds, infiltration of these cells and tissue is poor due to the 
architechture.203,211 As a comparison, knitted PLGA supplemented with MSCs were 
implanted within rabbit Achilles defects.  After 12 weeks, the scaffold allowed for 
native tissue ingrowth along with nearly a tensile strength that was 60% of the original 
tendon.212  Finally, with electrospinning, PLGA can be supplemented with other 
molecules, such as the growth factor FGF-2 during scaffold production.  This 
supplemented nanofiber mesh increased cell growth, tendon gene expression, and 
collagen deposition when compared to the mesh without supplementation.201  
As seen, there are many characteristics of a scaffold that must be considered 
when choosing an appropriate material for tendon tissue engineering.  Furthermore, 
often times, when choosing a scaffold, there are trade-offs between the characteristics 
such as: mechanical strength, cell attachment, and degradation rates among others.  As 
will be seen in future sections regarding mechanical stimulation, the scaffold stiffness 
can also play a large part of how the cells and tissue develops.  The material stiffness 
can  influence cell development and proliferation directly, or it can also affect how the 
cell senses and translates the mechanical signals into biochemical signals influencing 
the cell’s fate.213 
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3.2.2 Cells 
While scaffolds provide the support and base for a tissue engineered construct, 
cells are what make the construct a living tissue.  The cells are what create, deposit, and 
modify ECM along with adapting the tissue during the culture and regeneration 
process.162  They guide the tissue towards its ultimate result, an artificial tissue that can 
replace and regenerate an injured tissue.  They are what make the tissue alive. 
Primarily, the two cell types utilized in tendon tissue engineering are mature 
tenocytes and stromal stem cells.  However, stem cells provide a better option for tissue 
engineering of an artificial tendon. Research has shown that tenocytes can remodel and 
create tissue similarly to adult stem cells, however they proliferate at a slower rate than 
adult stem cells.214  This is a critical aspect of the cell source as a decellularized tissue 
or polymer must have and support a robust cell population at least initially to create 
sufficient high quality tissue to provide adequate mechanical properties and future 
tissue growth necessary for successful implantation.  In addition, without consistent 
stimulation, tenocytes have a tendency to drift phenotypically in vitro at later 
passages.215  Finally, it is much easier to acquire an aspirate of bone marrow for MSCs 
or biopsy of adipose tissue for adipose derived stem cells (ADSCs) from a patient as a 
cell source than it is to get a patient-specific source of tenocytes.    
However, these drawback have not stopped research into tenocytes as a tissue 
engineering stem cell source.175,216  Cao, et al. seeded PGA fibers with hen’s tenocytes 
and reported high amounts of tissue deposition after 6 and 10 weeks, however tensile 
strength was lacking (1.3 MPa).131  Tenocytes have also been used to repopulate 
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decellularized tendon tissue, but actually showed a decrease in ultimate tensile strength 
of the tissue.197 
Chong, et al. repopulated the tendon tissue with tenocytes and implanted them 
into rabbits.  In vivo, the donor tenocytes were eventually replaced by the body’s 
tenocytes after 12 weeks.217   The other previously mentioned group that utilized a 
tenocyte-seeded PGA construct also implanted their artificial tissues to test in vivo 
responses.  After 14 weeks, tissue deposition, alignment, and tenocyte population began 
to resemble natural tendon, but it was found that an immune response was elicited by 
the PGA.205 
As demonstrated by the previous results, tenocytes are utilized with mixed 
results.  Various stem cell types are by far more popular in the literature for tendon 
tissue engineering when compared to tenocytes.204,218–221 As the tenocyte originates 
from MSCs, they are a viable cell source to use for tendon tissue engineering.  MSCs 
may differentiate into many mesenchymal linages which include, but are not limited to:  
muscle, bone, cartilage, ligament, and tendon.222   This differentiation can be due to 
many different cues, either physical (ECM stiffness, mechanical stretching, fluid shear, 
etc.) or chemical (cytokines, other biological factors).180,223–230 Once committed, MSCs 
primarily progress to their terminal lineage state, however, there is some opportunity to 
switch lineages after initial commitment if early enough in the hierarchy of 
progression.231 They are found in many locations throughout the body, although 
primarily, and most plentiful, in the bone marrow.232 In addition to their capacity to 
differentiate, they are also therapeutic in their immature state with their ability to secrete 
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cytokines which can influence local cells and recruit distant ones for the healing 
process.233 
Tendon tissue engineering with MSCs can range from suspending them within a 
collagen gel and immediately implanting in a defect site in vivo to a mechanically 
stimulated PLGA scaffold seeded with MSCs in vitro.170,234  The MSC-seeded collagen 
gel did increase the mechanical properties of the defect, however, most of the cells were 
still rounded and non-aligned with the ECM, indicating little tenocytic integration or 
differention of the MSCs.170  This indicates that in vitro culture and stimulation 
(mechanical and/or chemical) may provide even further benefits to a MSC-seeded 
construct that allows for even better healing of a grafted defect.  This will be discussed 
in further detail in section 3.3.  As an example, a collagen gel seeded with MSCs and 
subjected to dynamic mechanical stimulation after 7 days did demonstrate increased 
ECM alignment, cell elongation, and increased expression of scleraxis, a marker of 
early tendon development.235  
Another niche of the stromal stem cell population is ADSCs.  These cells are 
isolated from adipose tissue through isolation of the stromal fraction from the adipose 
fraction of digested tissue and then further selection of ADSCs from the stromal 
fraction.236  This stem cell population has also be recently used in tendon tissue 
engineering and tendon repair.200,237,238  When cultured on a PLGA fiber scaffold in the 
presence of growth differentiation factor 5 (GDF-5), cell proliferation increased along 
with an increase in tendon related genes such as collagen type I, scleraxis, and 
tenomodulin.200  In addition, ADSCs have also been differentiated utilizing a 
decellularized, powdered form of tendon matrix as a supplement in culture.239   
32 
Finally, as discussed before, a population of stromal stem cells, TDSCs, is found 
within the tendon.  However, as their discovery has been only recent (2007), their cell 
density low compared to other stromal stem cell sources, and their autologous 
harvesting difficult, few studies specifically for tendon tissue engineering have been 
shown in the literature.69,74 Ni, et al. placed  TDSCs into patellar tendon wound sites 
with fibrin glue to improve healing.240  Their presence was gone within four weeks, 
however mechanical properties did improve compared to the negative controls.  The 
same group then attempted to make tissue engineered constructs out of TDSC cell 
sheets produced within culture flasks.241  The cells within the sheets did express genes 
characteristic of a tendon and did show improvement in vivo compared to the previouse 
fibrin glue/TDSC method as mechanical properties were more improved. 
 
3.2.3 Stimulation Techniques 
The healing process of tendons gives some insights on the importance of 
mechanical stimulation of tenocytes.  Lengthy immobilization adversely effects healing 
while controlled motion in rehabilitation can increase and hasten healing of the injured 
tendon.193,242,243 When strained in cultured dishes in vitro, tenocytes showed increased 
proliferation rates after 15 and 60 minute 5% strains at a 1 Hz frequency.244  In another 
study these stimulations also increased production of TGF-, PDGF, and FGF-2, 
growth factors involved in tendon development and tenocyte growth.81   Furthermore, 
tendons that were sliced 90% of their depth were cyclically stretched at 2 cycles/min 
continuously for 21 days.  After 14 days, new tenocytes were present mostly at the 
surface of the injured site, aligned in the direction of stretching at much higher rate than 
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the control tendons that were not stretched.  After 21 days, cell penetration was seen in 
the stimulated tendon while new tenocytes were only seen at the surface of the non-
stimulated tendons.245  In addition to increased proliferation and cellular activity, light 
strains (4%) are also shown to modulate and reduce inflammation responses in 
tenocytes.89  However, higher strains (8%) actually exacerbate the response.89  Finally, 
initial responses to high enough strain stresses can induce apoptosis, however, tenocytes 
have shown the ability to develop stress tolerance, as further stretching at the same 
parameters showed a decline in apoptosis rates.246 
Mechanical stimulation of MSCs also has beneficial outcomes.  2D stretching 
with strains between 2-8% can increase proliferation rates of MSCs.247,248 As an 
example, strains between 2% and 8% also increased proliferation rates in 2D cultures at 
1 Hz for up to 60 minutes.247 However, strains above 7.5% have also been shown to 
increase rates of apoptosis in 2D cultures.249  Therefore, there appears to be an upper 
limit to the benefit of strain in respect to MSC growth, which is near 8% (for 2D 
cultures).  When investigating morphology and migration, MSCs can align and elongate 
with the direction of stretching, characteristic of tenocytes within a tendon. 250   Cyclical 
stretching has also been shown to increase collagen types I and III gene expression 
along with increased collagen production. 250–252 Furthermore, tenascin C, a marker used 
for tenocytic differentiation of MSCs has been upregulated in 2D stretching studies. 
248,252,253 Zhang et al. demonstrated that collagen production and tenascin C gene 
expression is increased after only 24 hours of stretching at 10% strain and 1 Hz.250  
Finally, cyclical stretching can also inhibit adipogenesis of MSCs when strained at 2% 
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for 10 cycles/min for 6 hours, preventing an undesirable lineage for tendon tissue 
engineering.254 
In addition to mechanical stimulation, chemical stimulation also plays a vital 
role in cell fate and activity.  Typically in vivo this is done through cytokines, 
hormones, growth factors, and other small molecules.255–258  In tissue engineering, 
growth factors are often used in vitro to provide chemical stimulation to constructs to 
direct and promote growth of the artificial tissue.  Tendon tissue engineering has its 
own set of growth factors that influence development. 
GDFs -5, -6, and -7 are signaling molecules that have been shown to 
significantly participate in and regulate tendon and ligament development during 
embryogenesis.259  These factors are part of the TGF-superfamily.  This family 
progresses the signaling through both Smad and non-Smad pathways.260 Multiple FGFs 
also participate in the embryogenesis of tendons.261  FGF-2 also participates in early 
stages of healing to increase cell proliferation and collagen production.262  Therefore, it 
would be expected that these growth factors would also influence MSC and tenocyte 
activity in vitro implicating their use in tendon tissue engineering. 
Rat ADSCs were treated with GDF-5 in 2D culture to induce expression of 
tendon-related genes.  A 100 ng/mL dose increased ECM genes such as collagen type I 
and aggrecan along with early tendon markers such as tenascin-C and scleraxis, among 
others.236  Haddad-Weber, et al.  investigated the effect of increasing BMP-12 and 
BMP-13 (also known as GDF-7 and GDF-6 respectively) expression in MSC cultures 
through gene transfer with a focus on ligament differentiation.  However, ligaments and 
tendons share many similar characteristics and their results demonstrated many tendon 
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characteristics also. After 21 days, immunohistochemistry showed presence of collagen, 
fibronectin, decorin, elastin, scleraxis, tenascin, and tenomodulin, all ECM components 
of tendons.263  Another study also confirmed the ability of GDF-7 to induce tenocytic 
differentiation in MSCs.264  In addition, GDF-6, also known as cartilage derived 
morphogenic protein-2, has shown to increase the mechanical strength (35%) and 
healing rates of a rabbit Achilles tendon after 14 days, indicating an increase in healing 
capacity of tendon cells.265   
In addition to GDF family, other growth factors also promote tenocytic 
differentiation of stem cells along with increased activity in tenocytes themselves. A 
primary one is FGF-2.   Chen, et al. transduced MSCs with genes to overexpress FGF-2.  
These cells proliferated at a faster rate and expressed collagen type I, collagen type III, 
and scleraxis at higher rates than negative controls.  It was also found that the MAPK 
signaling pathway played an important role in the FGF-2 signaling cascade.266 Another 
member of the FGF family, FGF-5 has shown to increase tenocytic differentiation in 
equine ADSC along with FGF-2.  Both FGFs increased proliferation along with early 
tendon markers tenascin C and scleraxis.267 FGF-2 also can influence tenocyte 
development, it has been shown to increase proliferation and  influence migration in 
vitro.268 In vivo, acellularized dermal matrix treated with FGF-2 was placed into rats.  
After 6 weeks, the FGF-2 treated defects had significantly higher tensile strengths than 
negative controls and showed improved neotissue deposition, indicating increased 
migration and activity of tendon cells to the injury site.269 Insulin like growth factor 1 
(IGF-1) is thought to play a large part in tendon healing as it is expressed more strongly 
shortly after the initiation of tendinosis.  In vitro, IGF-1 has shown to increase tenocyte 
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proliferation and collagen production (both types I and III).270,271   In another study, 
PDGF-BB is proven to be beneficial to tenocytes.  Its application increased 
proteoglycan production, cell growth, and viability after administration of 
dexamethasone, which was shown to decrease these characteristics.272,273  Finally, a 
synergistic effect was seen when culturing tenocytes with IGF-1, PDGF-BB, and FGF-
2.  Tenocytes from the synovium were increased by 251% while a 100% increase was 
seen in epitenon and endotendon cells.274 
 
3.3 Tendon Tissue Engineering Bioreactors and Construct Stimulation 
A tissue engineered construct can be greatly improved upon if it is cultured in 
vitro as similar as possible to its physiological environment.  Bioreactors can provide 
much of this mimicry of the physiological environment by supplying the construct with 
any or all of the following: mechanical stimulation, biochemical stimulation, and media 
flow to improve mass transport properties.  The following sections will delve further 
into these aspects. 
 
3.3.1 Tendon Tissue Engineering Bioreactors 
Bioreactors aim to provide stimuli in vitro that mimic the physiological 
environment (mechanical and chemical) of native tissue to improve the properties of 
tissue engineered constructs.  By mimicking this environment, mature cells can retain 
their phenotype, stem cells can be differentiated, and growth of ECM and the cell 
population can be encouraged.160  In addition to encouraging tissue development, mass 
transport within the tissue can also be improved compared to a static culture, also 
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increasing the efficacy of the tissue culture.161 Some of these include spinner flasks, 
rotating wall vessels, and flow perfusion bioreactors.161 
The previous examples of bioreactors often introduce fluid shear to the 
construct.  This stimulus is mostly effective for bone and sometimes cartilage 
formation, and not necessarily tendon tissue engineering.275–277  In the body, tendons are 
most often stretched and relaxed as they transfer loads from the muscle to the bone.13 
To mimic this in vitro, most often tendon tissue engineering bioreactors are designed 
with a mechanical strain/stretch in the longitudinal direction.161  This has been 
introduced as either a constant tension of the construct or as a dynamic stretching and 
relaxing of the construct.46,218,219,278,279 Furthermore, the dynamic stimulation can be 
tuned further by its frequency, duration, and strain applied.  Short term culture effects 
by modifying some of these variables is the subject of chapter 4.  Sections 3.3.2 and 
3.3.3 will discuss in more detail the effects of mechanical and chemical stimulation on 
tissue engineered tendon constructs. 
 
3.3.2 Mechanical Stimulation  
 As with tendon treatments, it has been shown that immobilization can actual 
deter the healing process.242,243  Therefore, it stands to reason that mechanical 
stimulation in the form of stretching (mimicking the natural tendon environment) would 
be also beneficial in tendon tissue engineering.  Indeed, this is the case with both static 
and dynamic stretching.   
However, there is a difference in efficacy between the static and dynamic 
stimulation. In two separate studies, collagen fascicles were subjected to either static or 
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cyclical loads.  In both cases, loads near 40-50% of the peak stress of natural tendons 
encouraged the greatest increase in the mechanical properties of the fascicles such as 
tensile strength and elastic modulus. 280,281  It was concluded that that cyclical stretching 
caused larger increases compared to the static stretching. This was also seen in a MSC-
seeded PLGA constructs. A 6.7 N static load did not show any significant differences in 
collagen synthesis or cellular proliferation between loaded and non-loaded scaffolds234  
In addition, it was seen that the timing of the strain initiation (during seeding, after 
seeding, or two days after seeding) had no sign effects on those parameters either.234   
Indeed, these results that favor low intensity cyclic stimulation also seem to 
relate to other tendon tissue engineering studies utilizing mechanical stimulation.  
Strains between 1% and 5% have been shown to increase cell proliferation, gene 
expression of tendon related genes, tissue formation, and increase mechanical properties 
such as tensile strength, stiffness, and elastic modulus.179,180,235,282–285  However, many 
of these studies also vary other parameters such as frequency which can range up to 1 
Hz and duration of stimulation which ranges from 30 minutes per day to 8 hours per 
day.  Although many studies opt for shorter duration of stimulations of up to an 
hour/day to allow for recovery. 179,180,235,285 In terms of frequency, Joshi and Webb 
investigated on how frequency affects the construct’s ultimate tensile strength and 
elastic modulus.  They found that higher frequencies (1 Hz) were less beneficial and 
possessed lower ultimate tensile strengths and elastic moduli than their lower frequency 
stimulated counterparts.  Depending on the stimulation pattern, it was found that 0.1 Hz 
(resting periods at maximum tension) and 0.25 Hz (resting periods at no tension) were 
most beneficial.283 
39 
When utilizing a MSC-seeded HUV as a tissue engineered tendon construct, the 
aforementioned low intensity stretching (2% strain at a frequency of 1 cycle/min and 1 
hour per day) has been utilized to improve its properties.178–180   After 2 weeks of 
culture, tensile strength increased by 300% and a 20-fold increase in cell proliferation 
rates was observed.180  In addition, the use of cells and mechanical stimulation 
increased tissue formation and alignment of the new and existing ECM in the direction 
of the uniaxial stretching, making the construct more tendon-like in nature.179 Chapter 4 
will investigate how changing the stimulation duration and frequency affects the short 
term culture of cell seeded constructs. 
As discussed previously, high intensity stretching can be damaging to cells, 
inducing apoptosis.246,249  This phenomenon occurrence has also been shown in 
fibroblasts cultured in synthetic gels.  Cell alignment occurred in fibroblasts stretched at 
1 Hz for 24 hours in a biosynthetic polymer ProNectin, which contained RGD ligand to 
increase cell attachment. However, above 4% strain, few cells survived (8, 12%) and 
cell orientation began within 3 hours.286,287  
In other studies where high intensity stimulation was used some beneficial 
effects were observed. However, not as great as lower intensity stimulation. MSCs 
seeded on oligo(poly(ethylene glycol) fumarate) (OPF) were cultured for three weeks 
and subjected to a 10% strain at 1 Hz.  This strain was applied for 3 hours, then 
removed for 3 hours and this cycle was repeated throughout the culture duration.  This 
stimulation didn’t increase the cellularity on the construct as opposed to other 
stimulations, but the cells remained viable, and upregulated collagen type I, collagen 
type III, and tenascin C gene expression indicating that the cells weren’t actively 
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growing but were differentiating towards a tenocytic lineage.288  In another study, SIS 
membranes seeded with tenocytes were loaded with a cyclical 9% strain at 0.1 Hz for 
16 days.  The cyclical stimulation increased stiffness by 125% where the other groups 
with no cells or a static 9% strain did not significantly change the construct siffness.177  
However, cellularity did increase over the 16 days for all groups, but no significant 
difference was seen between the unloaded, static, and dynamic stimulation groups. 
Finally, the same Joshi and Webb study that investigated the effect of frequency of a 
polyurethane/fibroblast construct also looked at varying the strain up to 10%.  They 
found that 2.5% was the most beneficial in terms of increasing tensile strength and the 
elastic modulus of the construct while higher strains provided moderate improvements 
when compared to the static control.283 
 
3.3.3 Chemical Stimulation 
Although the effects of growth factors in tenocyte development have been 
shown both in vitro and in vivo (discussed in section 3.2.3), fewer studies have been 
performed specifically for enhancing a tissue engineered tendon construct. 
One of the main tenocytic growth factors, FGF-2 has been incorporated directly 
into the scaffold for delivery to MSCs on polymer scaffolds.201  A FGF-2 coated 
silk/PLGA scaffold demonstrated a positive effect on MSC activity and differentiation.  
The addition of FGF-2 maintained proliferation of the MSCs initially, and after two 
weeks, tenocytic differentiation was observed with increased tendon gene expression 
(collagen types I and III, fibronectin, and biglycan) along with mechanical properties 
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that had tendon-like characteristics (more viscoelastic and a more pronounced toe 
region) and increased tensile strength.202 
GDF-5 has also been utilized in tendon tissue engineering.  In one study, PCL 
was coated with collagen containing GDF-5 and seeded with stem cells.  The construct 
was then subjected to cyclic strain (10% at 0.33 Hz) for 2 days.  Collagen type I and 
scleraxis were increased by both stimuli, however no synergism was observed except 
the case of the the proliferation of the cells which was increased by 70% when both 
stimuli were applied.289  In another study, Basile, et al. utilized a tendon allograft coated 
with GDF-5 gene transfection vectors to induce healing in vivo.  These scaffolds induce 
more cell migration and proliferation along with enhanced cell healing compared to a 
control vector coated allograft.290 
No studies were found in the literature on angiogenesis and/or VEGF 
specifically for in vitro tendon tissue engineering.  However, it must be considered as a 
strategy in certain tendons if a construct is to be viable long term.  Even though 
tenocytes possess relatively low metabolism, they must have a consistent nutrient and 
oxygen source provided by a blood vessel network.13  For oxygen diffusion, cells must 
reside within  few 100 m of a blood vessel for viability.291  VEGF encourages blood 
vessel formation, and can also be enhanced further by other growth factors, such as 
PDGF-BB.292 
 
3.4 Conclusions 
Tissue engineering provides a future remedy for the need of an alternative graft 
solution in surgical treatments of tendon injuries.  The field can remedy many of the 
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issues with current graft treatments such as immune response, incomplete healing, and 
degraded function and integrity.  By creating a substitute artificial tissue, these issues 
need to be considered and addressed in the construct.  
These constructs are created using a combination of scaffolds, cells, bioreactors, 
and mechanical/biochemical stimulation.  Scaffold choices can vary among natural and 
synthetic materials, with pros and cons for each.  Both tenocytes and stem cells (MSCs 
and ADSCs) have been used in tendon tissue engineering, and with stem cells it is 
possible to obtain an autologous source of tenocyte inducible cells from the patient.  
However, even with a scaffold and cell source, the addition of stimulation either by 
mechanical or biochemical means, can generate improved neotissue.   
Both mechanical and biochemical stimulation have proven beneficial in tendon 
tissue engineering, with mechanical stretching within a bioreactor being the preferred 
method of stimulation.  It has been shown that a wide variety of stimulation is capable 
of increasing construct quality, however, lower intensity stimulations prove more 
beneficial.  Ultimately, even though the literature trends towards low intensity 
stimulation, every tendon tissue engineering system will be different with various 
scaffold materials, culture techniques, and mechanical variables. Therefore individual 
systems should be investigated to find the best stimulation parameter.  Chapter 4 will 
discuss how varying frequency and duration of the dynamic stretching can influence 
construct properties.  Unlike bone tissue engineering, where there is one key 
biochemical signal to assist in osteogenic differentiation (BMP-2 or dexamethasone), 
there is not a specific growth factor or combination of factors that has the same result in 
tissue engineering.  However, many growth factors have proven beneficial for tenocytic 
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development and differentiation such as FGF-2, GDF-5, GDF-6, and GDF-7 among 
others.  Chapter 5 will discuss biochemical influence on tenocytic differentiation of 
MSCs on a construct and an alternative source of biochemical stimulation. 
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Chapter 4:  The Effects of Varying Frequency and Duration of 
Mechanical Stimulation on a Tissue-Engineered Tendon Construct 
 
4.1 Introduction 
 Tissue engineering requires a three-pronged approach:  a cell source (mature or 
stem cells), a suitable scaffold to support cell and ECM growth, and cues provided by 
mechanical or chemical means to regulate cellular activity.293,294 The mechanical 
stimulation in terms of tendon tissue engineering is typically a uniaxial strain applied on 
the scaffold.218  This stimulation has been utilized with various magnitudes of strains, 
frequencies, and durations across research groups.  It is understood that beneficial 
stimulation can enhance cellular proliferation, promote tendon-like ECM production, 
and assist in the differentiation of stem cells towards a tenocytic lineage.247,295–297 
However, if improper stretching is applied, the construct can be degraded, due to cell 
death or declining ECM quality.249,298  Since mechanical properties and stimulation 
response can vary from construct to construct depending on system and techniques, it is 
important to elucidate which stimulation parameters are important for each system and 
how those parameters result in the most improved construct.  
 Previous research has investigated a decellularized HUV as a scaffold seeded 
with MSCs in a custom bioreactor that provides cyclical mechanical stimulation.  This 
stimulation was provided for 1 hour/day, at a 2% strain and 1 cycle/minute 
frequency.179  Compared to other studies, these conditions provide relatively low 
magnitude stimulation.  Although many studies have frequencies on the magnitude of 1 
cycle/minute, some studies do approach 1 Hz (60 cycles/min). 179,180,235,282–285   In 
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addition, durations of the stretching can range from 1 hour/day to 8 hours/day to the 
entire culture duration.  However, in chapter 3, it was discussed that shorter durations 
and lower frequencies tended to have more beneficial effects than their higher 
counterparts.179,180,235,283,285 The previous stimulations utilized in the HUV/MSC 
construct already resided in these lower ranges.  Ideally, the stimulation would approach 
the natural environment of a tendon, where stretching frequency and durations can 
vary.218  However, it has been shown that tendon ruptures can begin to occur at 6% 
strains.299,300  This corresponds with tendon tissue engineering data that reports that 
strains up to 5% were most beneficial for construct development. 179,180,235,282–285   
This study was done to determine the effects of changing the frequency and 
duration of stimulation on the HUV/MSC construct. It is hypothesized that varying the 
frequency and duration of stretching will affect the construct’s properties.  In addition, 
for early culture time points, mechanical stimulation is hypothesized to be more 
beneficial since the cells are still adapting to their new environment.  To test this, a 
slower and faster frequency compared to our previous studies along with a shorter and 
longer duration of stimulation was investigated.  
 
4.2 Materials and Methods 
4.2.1 Scaffold Preparation 
 Human umbilical cords were obtained from Norman Regional Hospital 
(Norman, OK).  The HUV was then extracted utilizing established protocols.178,179  
Briefly, the umbilical cord is mounted onto a steel mandrel and frozen at -80°C.  The 
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HUV was then extracted by a computerized lathe.  The resulting HUV had a diameter of 
6.75 0.25 mm and a wall thickness of 0.75 mm.   
 After extraction the HUV was inverted so that the remaining Wharton’s jelly 
region is on the interior of the scaffold.  The HUV is then decellularized, washed, and 
sterilized using previous procedures utilizing 1% sodium dodecyl sulfate (JT Baker, 
Center Valley, PA) and 0.2% peracetic acid solutions (Sigma Aldrich, St. Louis, MO). 
After adjusting the pH of the HUVs to physiological levels (7.2-7.4) utilizing phosphate 
buffered saline (Life Technologies, Grand Island, NY), they were stored at most for 1 
week at 4°C prior to use. 
4.2.2 MSC Extraction 
 Bone marrow MSCs were obtained from the femur and tibia of male Wistar rats 
(Harlan, Indianapolis, IN) using established procedures.301,302  After harvest, the bone 
marrow MSCs were cultured on 75 cm2 culture plates. After 80% confluency, cells 
were lifted and further passages were cultured on 75 cm2 flasks until ready for use.  
Cells were cultured with supplemented -MEM media in a humidified incubator at 
37°C and 5% CO2. The-MEM (Life Technologies) was supplemented with 10% FBS 
(Gemini Bio-Products, West Sacramento, CA) and 1% Antibiotic:Antimycotic (Gemini 
Bio-Products).  Passage 2 cells were utilized for all experiments. 
 
4.2.3 Experimental Design 
 The tissue constructs were prepared for placement into the bioreactor utilizing 
previous procedures.180 Briefly, MSCs were mixed with 2 mg/mL of collagen type I 
(BD Biosciences, San Jose, CA) at a density of 1 million cells/mL.  0.6 mL of this 
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mixture was injected into the HUV and custom stainless steel adapters were attached to 
seal the interior of the HUV.  The construct was then incubated at 37°C to allow for 
gelation of the collagen.  The constructs were then placed into the bioreactor pictured in 
figure 4.1.  These were then cultured for 3 or 7 days. 
At this point, mechanical stimulation was applied daily to the constructs 
according to the specific experimental group described in table 4-1.  Regular 
stimulation was performed at 2% strain for 1 hour/day at 1 cycle/minute meaning the 
construct was strained and relaxed 1 time per minute.180 Using this as a starting point, 
the stimulation frequency was varied under two different conditions:  1 cycle/2 minutes 
(slow) or 2 cycles/minute (fast).  In addition, the duration of the stimulation was also 
changed; constructs were subjected to either 0.5 hour/day (brief) or 2 hours/day 
(extended) durations at 1 cycle/minute. The regular stimulation was based upon 
previous studies which were shown to be beneficial to the HUV/MSC construct.  The 
variations were chosen to create a difference in mechanical stimulation without 
exposing the construct to too much stimulation, which has been shown to be detrimental 
to the tendon tissue engineered constructs.178–180,249,283 
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Figure 4.1: Depiction of the bioreactor.  The tissue constructs are attached via 
specialized adapters to the actuator generating the cyclical stretching.  Double 
reservoirs allow for continuous media circulation even during media 
replacement.  Inset:  View of the bioreactor containing tissue constructs in 
triplicate. 
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 Strain Frequency Duration 
Static None None None 
Regular 2% 1 cycle/minute 1 hour/day 
Slow 2% 1 cycle/2 minutes 1 hour/day 
Fast 2% 2 cycles/minute 1 hour/day 
Brief 2% 1 cycle/minute 0.5 hour/day 
Extended 2% 1 cycle/minute 2 hours/day 
Table 4-1:  Description of stimulation parameters for the various experimental 
groups. 
 
Controls included static culturing of the construct for 3 or 7 days.  This 
consisted of placing the MSC-seeded construct into the bioreactor, but not subjecting it 
to any dynamic stimulation.  After culturing, constructs were removed from the 
bioreactors and prepared according to the specific analysis being performed.   
 
4.2.4 Cellularity 
 A 0.5 cm section was obtained from the top, middle, and bottom of the construct 
for analysis.  These sections were then incubated overnight in collagenase type I (Life 
Technologies) dissolved in water to digest the ECM.  This resulting solution was then 
sonicated for 15 seconds and subjected to three freeze-thaw cycles to release the cells’ 
DNA content.  A Quant-iT PicoGreen dsDNA Assay kit (Life Technologies) was 
utilized to measure the DNA concentration by measuring the DNA/PicoGreen dye 
mixture’s fluorescence at 480/520 nm excitation/emission wavelengths on a Synergy 
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HT Multi-Mode Microplate Reader.  The resulting DNA concentration was then 
converted to a cell number using the measured DNA content in each cell (7 pg/cell). 
 
4.2.5 Mechanical Analysis 
 A uniaxial tensile testing frame (Untied Testing Systems, model SSTM-2K, 
Flint, MI) was used for mechanical testing.  Whole constructs were utilized for analysis.  
Samples were preconditioned for 5 cycles to remove hysteresis and then underwent 
failure analysis at 1%/s.  Extensions and force data were recorded utilizing 
accompanying software and were used to calculate stress and strain values for the 
construct.  To avoid end effects of the construct, analysis was only conducted on 
samples that failed away from the end regions. 
 
4.2.6 Histology 
 0.5 cm sections were fixed in 10% formalin (Azer Scientific, Morgantown, PA) 
and then embedded in paraffin (VWR, Radnor, PA).  The samples were then sectioned 
into 8 m slices and mounted onto Fisherbrand Selectfrost slides (Fisher Scientific).  
The slides were then stained with hematoxylin and eosin (Thermo Scientific) to observe 
ECM quality and orientation along with cell migration and shape.  Lateral sections of 
the construct were analyzed with ImageJ software and the FibrilTool plug-in to 
determine the fiber alignment.303 This was reported in terms of anisotropy of the fibrils 
where 0 indicates no directional dependence of fibrils while 1 indicates a complete 
alignment in one direction.  Cell penetration distances were also measured with ImageJ. 
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4.2.7 Gene Expression 
 Gene expression was measured utilizing real time polymerase chain reaction 
(RT-PCR).  Sections of the construct were homogenized utilizing a tenbroeck tissue 
grinder (Wheaton, Millville, NJ) and Trizol reagent (Life Technologies).  The mRNA 
was isolated from the homogenized Trizol solution per the manufacturer’s instructions.  
The RNA was then treated with DNase (Life Technologies) prior to reverse 
transcription.  Reverse transcription to DNA was performed utilizing a RNA-to-cDNA 
kit (Life Technologies) and Mastercycler ep realplex4 (Eppendorf, Hauppauge, NY).  
The resulting DNA was then amplified utilizing SYBR Green PCR Master Mix (Life 
Technologies) and specific genes were detected utilizing the primers (Integrated DNA 
Technologies, Coralville, IA) listed in table 2.236,304–310  Genes in the various 
experimental groups were normalized utilizing the housekeeping gene, glyceraldehyde 
3-phosphate dehydrogenase (GAPDH), and comparison between controls and the 
experimental groups were done utilizing the 2-Ct method of comparing experimental 
gene targets to the GAPDH housekeeping gene (Ct) and then comparing that change to 
a control experiment (Ct).311 
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 Forward Primer (5’ to 3’) Reverse Primer (5’ to 3’) 
GAPDH CCATTCTTCCACCTTTGATGCT TGTTGCTGTAGCCATATTCATTGT 
Biglycan CTGAGGGAACTTCACTTGGA CAGATAGACAACCTGGAGGAG 
Decorin TGGCAGTCTGGCTAATGT ACTCACGGCAGTGTAGGA 
COMP GTTTCCCGGACGAGAAGCTT ATCCTCCTGCCCTGAATTGG 
Collagen Type I ATCAGCCCAAACCCCAAGGAGA  CGCAGGAAGGTCAGCTGGATAG 
Collagen Type III AGGCTTTGATGGACGCAATG GCGGCTCCAGGAAGACC 
MMP-3 TCCCAGGAAAATAGCTGAGAACTT GAAACCCAAATGCTTCAAAGACA 
Elastin TAAATACGGAGCAGCAGGTG GCACCATATTTGGCAGCCTTAG 
Scleraxis CGAAGTTAGAAGGAGGAGGGT CGCTCAGATCAGGTCCAAAG 
Tenascin C GCTACTCCAGACGGTTTC TTCCACGGCTTATTCCAT 
Tenomodulin GGACTTTGAGGAGGATGG CGCTTGCTTGTCTGGTGC 
PPAR- CGGTTGATTTCTCCAGCATT AGCAAGGCACTTCTGAAACC 
Osterix CTTTCCCCACTCATTTCCTG CTAGGCAGGCAGTCAGAAG 
Collagen II CTCCAGGTGTGAAGGGTGAG GAACCTTGAGCACCTTCAGG 
Table 4-2:  Primers for gene expression analysis utilizing RT-PCR. 
 
4.2.8 Statistical Analysis 
 For all analysis, at least three tissue constructs were utilized (n 3).  For each 
construct, a sample from the top, middle, and bottom of the tissue was collected to 
determine a representative sample.  All results are reported as mean standard 
deviation.  Statistical significance was determined by applying two-way ANOVA 
methods with Bonferroni post tests to determine significance between individual groups 
and controls as appropriate. 
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4.3 Results 
4.3.1 Cellularity 
 Figure 4.2 shows the cellularity of the MSC/HUV constructs after 7 days of 
culturing for the stimulation frequency and duration changes.  The dashed line indicates 
the initial cell seeding density of 600,000 cells per construct.  Prior research has shown 
that the decellularization processes utilized does remove all existing cells, therefore, no 
additional contribution in cellularity is from the HUV itself.178,179 
 In most cases for the MSC/HUV construct, there was a significant increase in 
cell number compared to static controls, with the exception of the fast frequency (4.26 
0.32 million cells/construct) and the extended duration (3.98 0.39 million 
cells/construct).  However, there was no significant difference between the various 
stimulation groups.  The regular frequency of stimulation was shown to have the 
greatest increase in the number of cells (figure 4.2a) with 5.98 1.04 million cells/ 
construct, compared to the static culture, which only had 2.21 0.41 million cells/ 
construct, a 170% increase.  The brief duration (figure 4.2b) was the best group 
investigated in terms of cellularity, with 6.71 0.41 million cells/construct, a 300% 
increase.   
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Figure 4.2:  (a) Cellularity of the HUV/MSC construct as a function of the (a) 
frequency or the duration (b) of the stimulation.  * indicates p < 0.05 compared to 
the static control.  Data represented as mean standard deviation. A sample size 
of n ≥ 3 was used. Dashed line indicates initial seeding density of 600,000 
cells/construct.   
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4.3.2 Mechanical Analysis 
 Mechanical testing at 7 days (not pictured) revealed that the various stimulation 
groups did not result in significant changes compared to the static group.  In addition, 
varying the type of stimulation also did not have a significant effect.  Values ranged 
from 1.06 0.34 MPa, which was the fast group to 1.58 0.35 MPa, corresponding to 
the slow group. The ultimate tensile strengths were similar to values reported previously 
for 1 week stimulation of the MSC/HUV construct.179 
 
Figure 4.3:  Ultimate Tensile Strengths for the various experimental groups after 7 
days of culture. Data represented as mean standard deviation. A sample size of n 
≥ 3 was used. 
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4.3.3 Histology 
 Figure 4.4 shows lateral sections of the HUV after 7 days, demonstrating the 
alignment, or lack thereof, of the ECM fibers with the direction of stretching, indicated 
by the arrow. In figure 4.2a, the fast frequency was shown to have a non-significant 
increase in cell number compared to static controls, and in figure 4.4d, the fibrils are 
disorganized and random, similar to the static control.  The other stimulation groups 
demonstrated fiber alignment in the direction of stretching as indicated in table 4-3.  
Cross sections of the construct are given in figure 4.5.  Cells in all cases are primarily 
located in the interior wall of the constructs, with some migration into the walls, 
reaching a maximum distance of about 29% of the wall thickness (table 4-4).  
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Figure 4.4: Histological longitudinal sections of the construct after 7 days for (a) 
static control (b) regular stimulation, (c) slow frequency, (d) fast frequency, (e) 
brief duration, and (f) extended duration.  Arrows indicate direction of mechanical 
stretching.  Scale bar = 200 m. 
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Figure 4.5:  Histological cross-sections of the construct after 7 days for (a) static 
control (b) regular stimulation, (c) slow frequency, (d) fast frequency, (e) brief 
duration, and (f) extended duration.  Scale bar = 200 m. Arrows indicate cells 
within the scaffold. 
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Average Std. Dev 
Static 0.20 0.01 
Regular 0.44 0.01 
Slow 0.39 0.04 
Fast 0.19 0.01 
Brief 0.44 0.02 
Extended 0.46 0.07 
Table 4-3:  Anisotropy values for the lateral histological sections of the frequency 
and duration groups.  
 
 
Average Std. Dev 
Static 24% 5% 
Regular 16% 4% 
Slow 13% 4% 
Fast 29% 10% 
Brief 29% 8% 
Extended 29% 14% 
Table 4-4:  Maximum cell penetration depth as determined by histological cross 
sections of the frequency and duration groups. 
  
4.3.4 Gene Expression 
 Figures 4.6-4.9 show gene expression relative to a 3 and 7 day static control, 
utilizing the 2-Ct method.  The star indicates a significant difference to the static 
control.  Figure 4.6a shows significant biglycan upregulation in all stimulation 
situations except the regular stimulation, while an extended duration produced 
downregulation of decorin. Cartilage oligomeric matrix protein (COMP) was relatively 
unaffected by various frequencies and durations of stimulation.  Figure 4.7a shows that 
collagen production (both types I and III) was significantly upregulated (up to 10 fold 
magnitudes) in all situations, once again, with the exception of regular stimulation.  
Matrix metalloproteinase-3 (MMP-3) did not show any significant increases, and in all 
cases, elastin was downregulated or at similar levels to a static control.  Tendon marker 
expression is shown in figure 4.8a and the only stimulations that significantly 
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upregulates gene expression is the regular and slow frequencies for tenascin C, at a 1.6- 
and 2.23-fold level respectively.  
 
 
Figure 4.6: RT-PCR results for tendon-related ECM proteins at (a) 3 days culture 
time and (b) 7 days culture time compared to a static MSC/HUV construct control.  
* indicates p < 0.05 between experimental group and the control. Data represented 
as mean standard deviation. A sample size of n ≥ 3 was used. 
 
 
 
Figure 4.7: RT-PCR results for tendon-related ECM components at (a) 3 days 
culture time and (b) 7 days culture time compared to a static MSC/HUV construct 
control.  * indicates p < 0.05 between experimental group and the control. Data 
represented as mean standard deviation. A sample size of n ≥ 3 was used. 
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Figure 4.8: RT-PCR results for tendon-related differentiation markers at (a) 3 
days culture time and (b) 7 days culture time compared to a static MSC/HUV 
construct control.  * indicates p < 0.05 between experimental group and the 
control. Data represented as mean standard deviation. A sample size of n ≥ 3 was 
used. 
 
 
Figure 4.9: RT-PCR results for non-tendon related differentiation markers at (a) 3 
days culture time and (b) 7 days culture time compared to a static MSC/HUV 
construct control.  * indicates p < 0.05 between experimental group and the 
control. Data represented as mean standard deviation. A sample size of n ≥ 3 was 
used. 
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Fast stimulations resulted in a significant decrease (95% decrease) of tenomodulin 
compared to the static control. Figure 4.9a demonstrates a mixture of upregulation and 
down regulation.  Peroxisome proliferator-activated receptor gamma (PPAR- and 
collagen type II both saw significant downregulation for 3 days for both frequency 
variations and the brief stimulation. 
 Similar upregulation profiles of biglycan are seen in figure 4.6b, compared to 
the 3 day results.  In this case, all stimulations significantly upregulate biglycan 
expression.  However, for decorin and COMP, the observed upregulation for the various 
stimulations is not statistically significant (with the exception of the extended duration), 
while slow frequencies and extended durations produce significant downregulation of 
decorin.  The same trend continues between 3 and 7 days for collagen production.  
Figure 4.7b shows significant upregulation of collagen for all groups, with the exception 
of the fast frequency’s effect on collagen type I.  Once again, MMP-3 was near control 
levels and elastin was downregulated in all cases, significantly for slow and fast 
frequencies and extended stimulation durations.  However, compared to 3 days, more 
significant upregulation of tendon-specific markers was seen (figure 4.8b).  There was a 
significant increase in tenascin C for the slow frequency.  Significant upregulation was 
also seen in scleraxis with a brief stimulation and also tenomodulin in the case of fast 
frequencies and an extended duration.  Figure 4.9b shows that no non-tendon markers 
were significantly upregulated except for the regular stimulation, which significantly 
upregulated PPAR- expression.  Interestingly, the slow frequency was the only 
stimulation to significantly downregulate all non-tendon markers at 7 days when 
compared to the static control.    
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4.4 Discussion 
 There are many variables in terms of providing mechanical stimulation via 
stretching to a tissue-engineered construct, which include frequency, duration, and 
strain.  In this study we wanted to determine the sensitivity of the construct properties to 
frequency and duration changes from our previous studies, characterized by the regular 
stimulation present in this study.  By assessing the cellular proliferation rate, ECM 
quality via histology, mechanical properties, and gene expression of the cells present in 
the construct, the best stimulation settings used in this study are determined.   
 It has been shown that mechanical stimulation has beneficial effects in many 
cases with regard to cellular proliferation rates.247 However, in some of the 
experimental groups there are no significant benefits.  In figure 4.2a, both slow and 
regular frequencies of stimulation showed significant increases in cellular proliferation 
compared to the static controls with 125% and 170% increases compared to the static 
group respectively.  Comparatively, there is no significant change between the static 
and fast frequency groups.  An explanation is that the stimulation is beyond the 
acceptable level for cells that are trying to adapt to their new microenvironment. 
Another explanation for the decreased proliferation for the fast frequency group could 
be due to early differentiation. As MSCs differentiate, cell proliferation typically slows 
down.312  It has also been seen that MSCs can begin tenocytic differentiation after 7 
days after providing mechanical stimulation.235  In addition, figure 4.7c shows that 
tenomodulin, a later-term tendon marker is significantly increased at 7 days compared 
to the static MSC control group demonstrating a potential commitment to tenocytic 
differentiation.62 
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 Figure 4.2b demonstrates a similar relationship with duration.  In addition to the 
regular stimulation mentioned previously, the brief duration provided a significant 
increase in cellularity when compared to the static control with a 203% increase.  
However, the extended duration did not have as large of an effect on cellular 
proliferation.  This agrees with other studies that greater than one hour of stimulation 
can limit the beneficial effects of stimulation for MSCs.247 This may be due to 
differentiation, as was the case with the fast frequency, as after 7 days, compared to 
normal MSCs, a significant increase in tenomodulin gene expression was seen in the 
extended duration. The only other significant group to upregulate this gene was the fast 
frequency.  Another explanation is that the cells are undergoing apoptosis. It has been 
demonstrated that cell death increases in a time-dependent manner for up to 6 hours 
with stretching immediately following the stimulation in periodontal ligament cells.313   
The quality of fiber alignment appeared to be correlated with cellularity after 7 
days of culture, according to figures 4.2 and 4.4.  Significant increases in cellularity, as 
was the case with the regular, slow, and brief stimulations, resulted in ECM fibers 
aligned in the directions of stretching.  These aligned fibrils also appeared thicker.  
However, staining on the static control and fast frequency groups showed a more 
random orientation of fibers.  In addition, this fast frequency did not have a significant 
increase in cellularity compared to the static control.  This could be explained by the 
expression of collagens type I and III, shown in figure 4.7b.  Although MMP-3 activity 
was not significantly changed by the various experimental groups compared to a static 
control, collagen type I and III expression was increased, with the exception of collagen 
type I for fast stimulation frequency after 7 days.  Taken together, it appeared that the 
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slow, regular, and brief groups were producing more mature type I collagen, with fibrils 
aligned in the direction of stretching, due to the increased cellularity. In the case of the 
fast frequency, ECM production was of lower quality, and the cells demonstrated 
significant increase in collagen type III expression compared to controls while collagen 
type I was not affected.  In healing and developing tendons, collagen type III often 
precludes collagen type I, indicating that the fast frequency may stimulate more 
immature ECM compared to the other groups.314 Although the extended duration did 
produce thicker and aligned fibers in the direction of stretching like the other groups, it 
did not have a significant increase in cellularity.  This may be due in part to the 
significant increase in COMP gene expression after 7 days compared to static controls 
while no other experimental groups showed a significant increase.  COMP is thought to 
catalyze collagen fibrillogenesis and assist in ECM organization.315  This higher 
expression could possibly allow for the higher quality ECM without the higher cellular 
proliferation. Looking at cross-sections of the tissues in figure 4.5, cell penetration from 
the interior remains in the inner third to half of the construct.  This is in agreement with 
previous studies, where cell migration was not able to fully penetrate the HUV scaffold 
until 14 days of culture.178  Even though ECM quality did differ based on histology, this 
change is not represented by the ultimate tensile strength which was not significantly 
increased in any stimulation group.  It is possible that after only 7 days, not enough time 
has passed to allow for significant variations in mechanical properties due to stimulation 
changes. 
 In addition to collagen, other gene expression results also correlated with 
increased ECM production with mechanical stimulation. With the exception of the 
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regular stimulation at 3 days, biglycan expression was seen to be significantly increased 
for all groups and time points when compared to the static control.  Biglycan is a small 
leucine-rich proteoglycan found in many different tissues, it has a significant presence 
in tendons with spatial variances within the tendon itself.316  It provides structures and 
function to the tendon. Decorin is another proteoglycan that serves similar functions to 
biglycan.317  However, it is not upregulated in any case, and during the 3 day extended 
and 7 day slow and extended groups, is actually downregulated as seen by figures 4.6a 
and 4.6b.  This can be explained by the presence of Wharton’s jelly matrix on the 
interior of the scaffold, as this ECM is rich in decorin compared to biglycan.318  
Therefore, the cells seeded on the scaffold are possibly synthesizing more biglycan to 
make up for this deficit as they create and remodel ECM.      
In addition to those ECM components, elastin also possessed an overall trend 
regardless of experimental group or time point.  However, in this case, it was a decrease 
compared to static MSC controls as seen in figures 4.7a and 4.7b.  Elastin is present in 
tendons to provide its elastic properties and would typically be produced by cells. 
However, it is only present in about 0.8% of the tendon.319 This is in comparison to the 
elastin content of the HUV, which is on the order of 8%.320  As the elastin content of the 
vein is 10 times higher than a tendon, the cells do not have a need to produce much 
elastin for the ECM and their gene expression is reduced.    
 In addition to cellular proliferation and ECM production, mechanical stretching 
also provides cues to promote tenocytic differentiation. When investigating tenocyte 
markers as an indication of potential tenocytic differentiation, each experimental group 
saw a significant increase of one marker within 7 days.  One common early tenocytic 
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marker is tenascin-C, a glycoprotein present in high levels in regenerating and 
developing tendons and less so in mature, healthy tendons.3    After 3 days, the slow and 
regular stimulations show a significant increase in tenascin-C expression compared to 
static MSC experiments.  After 7 days, only the slow stimulation increases its 
expression of this gene.  Scleraxis is another early tendon markers. It is a transcription 
factor found in developing tendons during embryogenesis.321  Scleraxis was shown to 
be upregulated compared to the static control after 7 days in the brief stimulation.  This 
is in contrast to scleraxis being significantly downregulated after 3 days with the brief 
stimulation.  Finally, tenomodulin is a glycoprotein that is responsible for regulation of 
proliferation and development of tendon fibrils, along with being a later-term tendon 
development marker as was mentioned previously.50,62  Only the extended and fast 
stimulations after 7 days showed a significant increase in expression compared to static 
controls.   As previously mentioned, these two groups were the only groups to not see a 
significant increase in cell growth, implying a possibly more tendon-committed cell 
type being present in these two stimulations stunting cellular proliferation.   
 Non-tendon genes were also investigated to determine if any other 
musculoskeletal lineages may be present within the MSCs.  PPAR- was chosen to 
represent adipocytes, osterix for osteoblasts, and collagen type II for 
chondrocytes.276,322,323   Figure 4.9a shows that expression levels for all genes and 
stimulations were up and downregulated to various degrees, indicating a lack of 
committed lineages and a potentially still immature MSC phenotype.  However, after 7 
days, as seen in figure 4.9b, most of the expression levels were either at baseline or 
downregulated, with significant decreases for PPAR- for most stimulations, with the 
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exception of a significant increase in expression for regular stimulation.  Although these 
expression profiles do not prove tenocytic lineage, they demonstrate a tendency for the 
MSCs to move away from adipogenic, osteogenic, and chondrocytic characteristics.  
This was especially true for the slow stimulation which significantly downregulated all 
three genes. 
 
4.5 Conclusions 
 Varying the frequency and duration of stimulation did cause significant effects 
on the overall construct. 2 hours/day and 2 cycles/minute stretching slowed cellular 
proliferation, while the other stimulations all improved cell growth compared to no 
stretching.  This cell growth also was shown to directly contribute to ECM quality in 
terms of fibril alignment and diameter.  Gene expression analysis showed that the MSCs 
were remodeling the ECM to have more tendon-like qualities such as biglycan and 
elastin content compared to HUVs.   Tendon and non-tendon markers demonstrated 
little to no potential differentiation after 3 days of the MSCs, however at 7 days, most 
stimulations upregulated various tenocytic markers while inhibiting non-tendon 
phenotypes.  Overall, shorter durations and slower frequencies such as the 0.5 hour/day 
and 0.5 cycles/min stimulations, allowed for increased cellular proliferation while 
maintaining the ability to promote tenocytic differentiation at 7 days.   
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Chapter 5:  Improvement of a Tissue-engineered Tendon Construct by 
Supplementation with Mature Tencoytic Extract 
5.1 Introduction 
 As discussed previously, typically in tendon tissue engineering mechanical 
stimulation is utilized in the form of cyclical stretching.  This has proven to improve 
cellularity, construct quality, and mechanical properties.179,180 In addition, there has 
been some investigation into the use of growth factors as an additional stimulation 
mechanism for cell development and differentiation into a tenocytic lineage.  Some of 
the growth factors include FGF-2, GDF-5, GDF-6, and GDF-7 among 
others.200,263,267,289,290  
However, there is not one definitive growth factor or mixture of growth factors 
found that is directly responsible for tenocytic differentiation of stem cells, such as 
BMP-2 for osteogenesis.324 As an alternative to supplementing with one or a few 
specific growth factors, we propose the use of extract from mature tenocytes.  Extract is 
the internal proteins and genetic material found inside the cell.325,326  These molecules 
can be released into solution by lysing the mature cell and releasing the cell internals 
into solutoin.   
Cell extract has been shown to possess growth factors stored within the cell in 
different cell types.325,327  It also possesses nucleic acids and transcription factors 
contained within the cell.326,328  All of these molecules can potentially affect stem cell 
differentiation.  Previously, stem cells have been differentiated by being exposed to 
extract from cardiomyocytes and pneumocytes.326,329  By supplementing the MSCs with 
tendon extract, it is hypothesized that cell fate can be influenced at an early stage, either 
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through interactions of the growth factors or incorporation of the transcription factors 
and genetic material.  This extract could be obtained from the patient prior to tendon 
repair with the tissue-engineered tendon, as it has been shown that tendon biopsies can 
be performed with minimal donor site morbidity.330 
 This study aims to show that mature tendon cells should possess the proteins and 
genes necessary to influence stem cell development into a tendon lineage.  By applying 
these molecules to the stem cell culture, it is hypothesized that they should significant 
increases cell growth and differentiation and construct properties, in addition to the 
benefits of mechanical stimulation.  
 
5.2 Materials and Methods 
5.2.1 MSC and Tenocyte Extraction 
 MSCs were obtained utilizing similar techniques as in chapter 4.  During bone 
marrow MSC isolation, the Achilles tendon of the rats was also harvested to obtain 
mature tenocytes.  This tendon was then digested overnight with 200 U/mL of 
Collagenase Type I (Life Technologies) dissolved in -MEM (Life Technologies) 
supplemented with 10% fetal bovine serum and 100 U/mL antibiotic:antimicotic 
(Gemini Bio-Products, West Sacramento, CA).  The solution was then transferred to 25 
cm2 flasks (Fisher Scientific, Hampton, NH) for further cell culture.  After 80% 
confluency (between 1-2 weeks), cells were lifted and further passages were cultured on 
75 cm2 flasks until ready for use.   
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5.2.2 Scaffold Preparation 
 Scaffolds were prepared similarly to chapter 4.  Figure 5.1a shows the vein 
being extracted utilizing the mechanical lathe and the seeded, decellularized HUV prior 
to bioreactor culture is pictured in figure 5.1b. 
 
Figure 5.1: a) A partially lathed umbilical cord exposing the HUV.  b)  Image of an 
HUV seeded with collagen gel/MSCs.  c)  Constructs cultured within the 
bioreactor. 
 
5.2.3 Extract Preparation 
 Confluent tenocytes (or up to 90% confluency) were used to obtain the tenocytic 
extract solution.  The process followed modified previous protocols.326 Cells were lifted 
from the flask utilizing 0.25% trypsin-EDTA (Life Technologies, Grand Island, NY) 
and spun down in -MEM to neutralize and remove the trypsin.  The resulting cell 
pellet was then washed twice with cell lysis buffer.  This buffer consisted of 50 mM 
NaCl, 5 mM MgCl2 , 20 mM Hepes, and 1 mM dithiothreitol at a pH of 8.2 (Sigma 
Aldrich, St. Louis, MO).326 After washing, cells were lysed in the buffer with liquid 
nitrogen snap freezing and sonication.  The resulting solution was then centrifuged and 
the supernatant was transferred to a new centrifuge tube to remove cellular debris.  A 
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Bradford assay was performed and a protein concentration of 38.2 4.6 mg/mL was 
used for supplementation. 
 
5.2.4 Experimental Design 
 The tissue constructs were prepared for placement into the bioreactor based 
previous procedures along with addition of tenocytic extract.180 MSCs were mixed with 
2 mg/mL of collagen type I at a density of 3 million cells/mL. Extract was added to this 
solution to obtain a concentration of 16.8 mg/mL according to a previous protocol.326   
0.6 mL of this mixture was injected into the interior of the HUV and incubated at 37°C 
for two hours to allow for setting up of the collagen gel.  The constructs were then 
placed into the bioreactor pictured in figure 1c.  Within the bioreactor, constructs were 
subjected to either a static culture or cyclical stretching.  This stretching was a 2% strain 
for 0.5 hours/day at 0.5 cycle/min.  Culture times were for 7 and 14 days. 
 Experimental controls included MSC-seeded constructs without the extract 
supplementation and mature tenocytes cultured with the HUV.  The constructs were 
subjected to the same culture times and stimulations as the extract-supplemented 
groups.   
 
5.2.5 Cellularity 
 Cellularity analysis was done as described in chapter 4. 
 
5.2.6 Mechanical Analysis 
 Mechanical analysis was done as described in chapter 4. 
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5.2.7 Histology 
 Histology was performed in the same manner as chapter 4. 
 
5.2.8 Gene Expression 
 RNA and DNA were isolated and reverse transcribed respectively utilizing the 
same methods as chapter 4.   The genes analyzed for this study were:  GAPDH 
(housekeeping gene), collagen type I, collagen type III, elastin, scleraxis, COMP, and 
tenomodulin.  These primers had the same sequences as in chapter 4.  RT-PCR and cell 
preparation was also done the same as in chapter 4.  The analysis was also done 
utilizing the 2-Ct method with both tenocyte and non-supplemented MSC constructs as 
comparisons.311 
 
5.2.9 Statistical Analysis 
 At least 3 samples were performed for each analysis.  To get a representative 
sample, sections from the top, bottom, and middle of the constructs were analyzed.  All 
results are reported as mean standard deviation.  Statistical significance was 
determined by applying two-way ANOVA with Bonferroni post tests to determine 
significance between individual groups and controls as appropriate. A p < 0.05 was 
used to determine significance.   
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5.3 Results 
5.3.1 Cellularity 
 As seen in figure 5.2, cell growth was significantly higher after 14 days for both 
types of MSC cultures when stimulated mechanically.  After 14 days, MSCs not 
cultured with extract increased by 503%.  This construct had 10.86 1.12 million cells, 
a 212% increase over the 7 day dynamic culture (3.48 0.19 million cells) and a 74% 
increase over the static 14 day culture (6.23 2.21 million cells). Meanwhile, HUVs 
seeded with MSCs and supplemented with extract possessed 14.84 1.36 million cells 
after 14 days dynamic culture, a 127% increase from the 7 day dynamic culture (6.52 
0.36 million cells).  In addition, the extract supplemented experimental group 
possessed significantly higher cell numbers when cultured dynamically compared to the 
non-supplemented groups.  Tenocytes cultured in the HUV did not show significant 
changes from 7 to 14 days or if cultured with stimulation, actually decreasing from 6.43 
0.42 to 5.94 2.06 million cells in 7 to 14 day dynamic cultures.   After 14 days of 
dynamic culture, both of the MSC experimental groups had a significantly higher 
amount of cells compared to the tenocyte group. 
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Figure 5.2:  Cell density of experimental construct groups.  * indicated p < 0.05 
between indicated groups. Data represented as mean standard deviation. A 
sample size of n ≥ 3 was used. 
 
5.3.2 Histology 
 Figure 5.3 presents cross section views of the HUV construct during static 
culture.  Figures 5.3a, 5.3c, and 5.3e show that the cells remain on the inner portion of 
the tissue where they were seeded after 7 days of culture for non-supplemented, extract 
supplemented, and tenocytic groups respectively.  After 14 days of culture, the cells 
have shown to migrate through the construct towards the outer walls, penetrating the 
tissue (figures 5.3b, 5.3d, 5.3f) to varying degrees given in table 5-2. 
Figure 5.4 shows the quality and alignment of the ECM of the statically cultured 
constructs and table 5-1 quantifies the fibril alignment in terms of anisotropy.  The non-
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supplemented group after 7 days (figure 5.4a) and 14 days (figure 5.4b) had little to no 
alignment of the fibers in the direction of stretching.  And although the fibrils after 14 
days do appear thicker, large amounts of void space are still present.  Figures 5.4c and 
5.4d show the extract supplemented groups after 7 and 14 days of static culture 
respectively.  These groups did have increased amounts of ECM present, and after 14 
days, some alignment was present, more so than the non-supplemented groups.  
However, the random structure was still present.  The tenocyte static cultures are 
depicted in figures 5.4e (7 days) and 5.4f (14 days).  These constructs had thinner fibrils 
than the supplemented group, however, alignment in the direction of stretching was 
greater than the non-supplemented group and similar to the supplemented group after 14 
days. 
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Figure 5.3: Cross-sectional views of the tissue samples at 4x magnification for 
static constructs.  Scale bar is 500 m. a – 7 days non-supplemented controls, b - 14 
days non-supplemented controls, c - 7 days extract supplemented controls, d - 14 
days extract supplemented controls, e – 7 day tenocyte culture, f – 14 day tenocyte 
culture.  Arrows indicate cells within the scaffold. 
  
78 
 
Figure 5.4:  Lateral section views of the tissue samples at 10x magnification for 
static constructs.  Scale bar is 200 m. a – 7 days non-supplemented controls, b - 14 
days non-supplemented controls, c - 7 days extract supplemented controls, d - 14 
days extract supplemented controls, e – 7 day tenocyte culture, f – 14 day tenocyte 
culture 
  
79 
 
  
 
Static Dynamic 
 Mean 
Std  
Dev Mean 
Std 
Dev 
7 Day Non-Supplemented MSC 0.15 0.03 0.21 0.01 
14 Day Non-Supplemented MSC 0.11 0.05 0.49 0.05 
7 Day Supplemented MSC 0.11 0.01 0.38 0.02 
14 Day Supplemented MSC 0.31 0.01 0.44 0.02 
7 Day Tenocytes 0.33 0.02 0.27 0.03 
14 Day Tenocytes 0.40 0.04 0.43 0.03 
Table 5-1:  Anisotropy data for the lateral sections of the extract 
experimental groups. 
 
Static Dynamic 
 Mean 
Std  
Dev Mean 
Std 
Dev 
7 Day Non-Supplemented MSC 10% 1% 12% 5% 
14 Day Non-Supplemented MSC 45% 21% 54% 18% 
7 Day Supplemented MSC 8% 1% 12% 3% 
14 Day Supplemented MSC 69% 11% 73% 8% 
7 Day Tenocytes 14% 4% 21% 12% 
14 Day Tenocytes 51% 10% 60% 7% 
Table 5-2: Maximum cell penetration for the cross sections of the 
extract experimental groups. 
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Figure 5.5 shows cross sections of the dynamically cultured constructs.  In all 
three cases after 7 days (figure 5.5a, 5.5c, 5.5e), the majority of the cells still resided on 
the surface of the interior of the tissue where they were seeded.  However, after 7 days, 
they began to penetrate throughout the scaffold.  The tenocyte culture (figure 5.5f) after 
14 days still had most of its cells at the surface, however, there was a portion of cells 
that penetrated nearly 60% of the way through the scaffold.  On the other hand, both 
MSC groups has a large portion of their cells penetrate the scaffold.  The non-
supplemented controls penetrated nearly 54% through the scaffold, similar to the 
tenocyte control, but had a much larger amount of cells penetrate.  The extract 
supplemented construct had nearly 73% of the scaffold depth penetrated with cells. 
 The lateral sections in figure 5.6 indicate fiber alignment of extracellular matrix 
along with the direction of stretching as indicated by the arrows.  After 7 days, all the 
constructs demonstrate some alignment with the direction of stretching, but the ECM is 
still somewhat disorganized and/or wavy in appearance (figures 5.6a, 5.6c, 5.6e).  The 
non-supplemented culture in figure 5.6a especially appears somewhat more random in 
appearance compared to the tenocyte and extract supplemented constructs.  After 14 
days however, a much more aligned extracellular matrix (ECM) is seen along with a 
greater abundance of ECM.  This is especially pronounced in figure 5.6d, the extract 
supplemented MSC construct, with a dense connective tissue-like appearance.  In 
addition, some purple stained nuclei appear elongated, indicating a tendon like 
phenotype.  For comparison, figure 5.7 shows a rat tendon, in which fibers are aligned 
in the longitudinal direction of the tendon along with a sparse population of cells.  
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Figure 5.5: Cross-sectional views of the tissue samples at 4x magnification for 
dynamic constructs.  Scale bar is 500 m. a – 7 days non-supplemented controls, b 
- 14 days non-supplemented controls, c - 7 days extract supplemented controls, d - 
14 days extract supplemented controls, e – 7 day tenocyte culture, f – 14 day 
tenocyte culture. Arrows indicate cells within the scaffold. 
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Figure 5.6: Lateral section views of the tissue samples at 10x magnification for 
dynamic constructs.  Scale bar is 200 m. a – 7 days non-supplemented controls, b 
- 14 days non-supplemented controls, c - 7 days extract supplemented controls, d - 
14 days extract supplemented controls, e – 7 day tenocyte culture, f – 14 day 
tenocyte culture. 
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Figure 5.7: Histological staining of rat Achilles tendon.  Scale bar is 100 m. 
 
5.3.3 Mechanical Analysis 
 Ultimate tensile strength of the constructs is shown in figure 5.8.  All groups had 
significant increases in mechanical strength from the decellularized HUV which had an 
ultimate tensile strength of 0.47 0.19 MPa.  None of the static culture groups showed 
significant increases from 7 to 14 days, but did show increasing trends.  Fourteen days 
static cultures resulted in 1.73 0.56 MPa, 2.1 0.33 MPa, and 1.84 0.67 MPa for 
MSCs without extract, MSCs cultured with extract, and tenocyte cultures respectively.  
The same groups possessed ultimate tensile strengths of 2.6 0.6 MPa, 3.45 0.70 
MPa, and 2.38 0.91 MPa respectively after 14 days of dynamic culture.  Each of these 
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increases were significant in respect to the 7 day dynamic culture period.  In addition, 
the extract supplemented group possessed higher ultimate tensile strengths than the non-
supplemented (33% larger) or tenocyte group (45% larger).   
 
Figure 5.8: Ultimate tensile strength of the various construct groups.  * indicates p 
< 0.05 between groups. Data represented as mean standard deviation. A sample 
size of n ≥ 3 was used. 
 
5.3.4 Gene Expression 
 Figure 5.9 shows the gene expression analysis for the extract supplemented 
controls.  The static supplemented experimental group compared to the non-
supplemented MSC group is given in figure 5.9a.  Although most of the tendon-related 
genes are upregulated after 7 and 14 days (only tenomodulin after 7 days is 
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downregulated), none are significantly changed from 7 to 14 days.  Figure 5.9b 
compares the static extract supplemented group to tenocytes.  In this comparison, 
expression levels are similar to tenocytes; however scleraxis expression is upregulated 
after 7 days compared to tenocytes but is downregulated after 14 days, a 22 fold change.  
Alternatively, COMP is downregulated after 7 days but has a significant a 5.6 fold 
increase compared to the 7 day time point and is upregulated after 14 days. 
 
Figure 5.9:  Gene expression of cells for selected tendon related genes.  * indicates 
p < 0.05 between groups. Data represented as mean standard deviation. A 
sample size of n ≥ 3 was used.  a) Statically cultured and extract-supplemented 
constructs compared to non-supplemented MSCs, b) Statically cultured and 
extract-supplemented constructs compared tenocytes, c) dynamically cultured and 
extract-supplemented constructs compared to non-supplemented MSCs, d) 
dynamically cultured and extract-supplemented constructs compared to tenocytes. 
 
Figure 5.9c provides gene expression of the mechanically stimulated extract 
supplemented constructs compared to the non-supplemented MSC constructs.  After 7 
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days, only collagen type 1 and COMP were upregulated compared to the non-
supplemented controls (a 1.13 fold and 1.22 fold increase respectively).  Alternatively, 
collagen type III (4.73 fold), elastin (13.07 fold), scleraxis (5.61 fold), and tenomodulin 
(1.89 fold) had decreased expression.  With 14 days of culture, only COMP expression 
decreased from 7 days.  However, collagen type III was still slightly downregulated.  
Each of the changes between 7 and 14 days was significant with the exception of 
tenomodulin. 
 When comparing the mechanically stimulated supplemented constructs to the 
tenocyte control in figure 5.9d, after 7 days, only collagen type I, collagen type III, and 
tenomodulin were upregulated.  This was a 3.87, 1.50, and 1.11 fold increase 
respectively.  All other gene expressions were downregulated.  However, after 14 days, 
both collagens were downregulated while elastin (7.53 fold) and scleraxis (1.05 fold) 
were upregulated.  COMP and tenomodulin remained downregulated and upregulated 
respectively. Significant decreases between 7 and 14 days for collagen type I and 
collagen type III were present while all other genes were significantly upregulated 
compared to the earlier time point. 
 
5.4 Discussion 
 It was desired in this study to investigate an alternative means for chemically 
stimulating the MSC/HUV construct to supplement mechanical stimulation in tendon 
tissue engineering.  Growth factors have been successfully isolated from lysed mature 
cell lines.325 Furthermore, it has been previously shown that extract which has been 
shown to contain genetic material and stored proteins (such as growth factors and other 
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signaling molecules) can influence stem cell fate towards the mature cell 
lineage.326,329,331,332 This is done by the stem cells incorporating genetic material for 
reprogramming and signaling resulting from the soluble factors such as growth factors 
produced by the mature cell line. Tenocytes have been shown to produce many of the 
growth factors such as TGF-1, BMP-12, and FGF-2 present in native tendon.333  
Although many of these molecules have half-lives of hours (FGF-2) to a day (some 
proteins found in the cell), the initial exposure to the growth factors and any 
incorporation of genetic material and transcription factors would have positive tenocytic 
effects on the MSCs.334–338 By promoting a tenocytic lineage within our construct, we 
saw increases in cellular proliferation, tenocytic gene expression patterns, and ultimate 
tensile strength when MSCs were supplemented by tenocytic extract.   
 The tenocytic extract did have a mitogenic effect on MSC-seeded HUVs and 
was synergistic with mechanical stimulation as seen in figure 5.2.  After 14 days, 
constructs that were supplemented with extract and mechanically stimulated had 
significantly higher amounts of cells compared to the non-supplemented group.  In 
addition the dynamic stimulation also provided significant increases over static 
culturing in the supplemented group.  Furthermore, the dynamically cultured and extract 
supplemented constructs also possessed a significantly larger amount of cells compared 
to tenocytes after 14 days.  Tenocytic extract has been shown to stimulate DNA 
synthesis and contains IGF-1.339  In addition, IGF-1 is known to increase MSC 
proliferation rates.340     As for the tenocyte culture itself it has been seen that at some 
limiting concentration, tenocytes stop proliferating within a 3D collagenous 
construct.285 This also occurred in the HUV which contains mostly collagen other 
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components, as the tenocytes possessed the highest amount of cells after dynamic 
stimulation of 7 days, but did not demonstrate any better changes. Our explanation for 
this behavior may be that by repopulating the construct with mature tenocytes, the cells 
may grow rapidly at first, but reach the concentration within the scaffold that resembles 
a healthy tendon, thereby halting their proliferation rates.  This would result in little 
change from 7 to 14 days. 
 Similar trends were seen with the ultimate tensile strength of the constructs. 
Although, seeding with cells was beneficial enough to significantly increase the tensile 
strength of the decellularized HUV, significant increases within the experimental 
groups did not occur until after 14 days of culture with mechanical stimulation.  In this 
situation, both MSC-seeded groups demonstrated significant increases compared to 
earlier time points and the same day static group.  Once again, the extract supplemented 
group with mechanical stimulation possessed the best tensile strength, exhibiting a 
degree of synergy between the two stimulation techniques.  It had a 3.45 0.70 MPa 
ultimate tensile strength, and was significantly stronger than the static 14 day culture, 
either 7 day culture, and 14 day mechanically stimulated non-supplemented and 
tenocyte groups.   
 These tensile strength gains did correlate with the histological images with 
higher mechanical strengths correlating with more aligned ECM.  When looking at 
figure 4 compared to figure 5.6, the lateral histological images, dynamic culturing 
resulted in more aligned fibers in the direction of stretching.  Additional differences 
were seen in the mechanically stimulated lateral section images in figure 5.6.  After 7 
days, all three groups had some aligned ECM fibers in the direction of stretching, but 
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there was still random orientation, reminiscent of the decellularized HUV scaffold 
(figures 5.6a, 5.6c, 5.6e).178,180 However, after 14 days, differences started appearing.  
Both MSC seeded groups (figures 5.6b and 5.6d) had more tissue formed in the images 
compared to the tenocytes (figure 5.6f) and the fibers, although fairly well aligned in the 
tenocyte group, were more aligned with the MSC groups.  Between the supplemented 
and non-supplemented groups there was also some difference, with the extract 
supplemented group (figure 5.6d) possessing a much denser connective tissue 
appearance that resembles natural tendon tissue.  This similarity can be seen in a 
magnified image of a rat Achilles tendon seen in figure 5.7.  
 The gene expression results for the extract supplementation when compared to 
non-supplemented control and tenocyte culture in figure 5.9 also relates to the previous 
data.  In figure 5.9a, it is seen that the tendon extract does positively influence tendon 
gene regulation without mechanical stimulation as all genes are overexpressed except 
for tenomodulin at 7 days compared to non-supplemented MSCs.  However, there are 
no significant changes from day 7 to day 14, corresponding to no significant increases 
in mechanical strength among static groups.  Figure 5.9b shows that compared to 
tenocytes, static culture of extract supplemented construct results in tendon gene 
expression similar or less than tenocytes.   In fact, scleraxis, an early marker of tendon 
development is actually downregulated after 14 days compared to the tenocyte 
control.341   
However, gene expression experienced greater changes when mechanical 
stimulation was also applied.  In figure 5.9c, we see that collagen type I is upregulated 
compared to the non-supplemented group at both 7 and 14 days, while it is only 
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upregulated compared to the tenocytes at 7 days.  After 7 days of culture, the extract 
supplemented group had more ECM, which is primarily made out of collagen type I 
compared to the other two groups according to the histological images.  After 14 days, 
both MSC groups had a more connective-tissue like appearance, but the extract 
supplemented group had more tightly packed fibrils.  On the other hand, as less ECM is 
present in the tenocyte culture, the cells may be increasing the expression of collagen 
type I genes to produce more matrix to fill the void space at 14 days.  Also, tendon 
development progression is marked by increased collagen production, another reason 
why the extract supplemented group may have seen a higher expression of collagen 
type I compared to the non-stimulated group, as it has increased tendon-like 
characteristics.342  Alternatively, collagen type III is downregulated at both 7 and 14 
days compared to the MSC control, while it is upregulated compared to tenocytes after 
7 days and then downregulated at 14 days.  Collagen type III is often found in higher 
concentrations at the beginning of tendon development and healing and decreases as it 
matures.343  An increase of collagen type III when compared to normal MSCs between 
7 and 14 days indicate a tendency towards more of a tenocytic lineage.  A decrease 
when compared to tenocytes could indicate more developed ECM for the supplemented 
MSC culture, which was also seen in the histological images.   
 Other gene expression targets investigated indicate an increase in tendon-like 
development for the extract supplemented group, especially after 14 days.  Elastin is 
often present in well-developed fibrils early on in the tendon development cycle.342  The 
supplemented MSCs demonstrate a significant increase in the expression of elastin from 
7 to 14 days.  However, the gene is only upregulated compared to tenocytes or MSCs 
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after 14 days.  This may be due to an increased differentiation level compared to the 
non-supplemented group.  In addition, the tenocytes may express less elastin genes due 
to their mature state compared to the differentiating MSCs. 
 COMP helps catalyze fibrillogenesis of collagen fibers in tendons.344  However, 
when compared to the tendon culture, it is downregulated in extract supplemented 
constructs after both 7 and 14 days, albeit with a significant increase in expression 
between 7 and 14 days.  It has been shown that tenocytes when exposed to mechanical 
stimulation or mechanical stimulation and TGF-1 and TGF-3 increased production of 
COMP.345  Therefore, the mature tenocytes could be expressing much more COMP 
compared to stem cells in response to the mechanical stimulation provided since the 
stem cells were still immature and undifferentiated, especially at 7 days.  The fact that 
the expression in the supplemented group increases compared to the tenocytes could 
indicate differentiation and progress towards a tenocytic lineage.  When compared to 
the non-supplemented control, the supplemented MSCs actually demonstrated a 
significant decrease in COMP expression.  As seen in figure 5.6, after 7 days, the fibrils 
in the supplemented group (figure 5.6c) are thicker and more aligned, while in the non-
supplemented group (figure 5.6a) are much more random, indicating more collagen 
fibril production for the supplemented group.  However, after 14 days, the extract 
supplemented group (figure 5.6d) is denser and has less individual fibrils surrounded by 
void spaces as seen in figure 5.6b for the non-supplemented group.  The presence of 
more individual fibrils and available void space indicates a greater need for collagen 
production and, therefore, COMP production. 
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 Scleraxis is an early marker of tendon development.341  It has also been shown 
that its production is increased in injured tendons after exposure to mechanical 
stimulation.346  Taken together, mechanical stimulation and differentiating MSCs 
should express high levels of scleraxis.  When compared to non-stimulated MSCs, the 
extract groups show similar trends as was seen in elastin, with a downregulation of the 
gene after 7 days and a significant increase in the expression after 14 days, when it is 
upregulated compared to the control, indicating that the extract may slightly delay 
differentiation in the construct.  When comparing with the tenocyte group, the same 
effect is seen, with a significant increase in scleraxis expression between 7 and 14 days 
with extract supplementation, to the point it reaches a nearly identical level as the 
tenocytes.  As the previously mentioned research has shown that tenocytes themselves 
will increase scleraxis expression with mechanical stimulation, so a similar level of 
expression between the two groups indicate a high level of scleraxis production for the 
extract group. Furthermore, when compared to the static groups in which the scleraxis 
expression decreased from 7 to 14 days, it appears that mechanical stimulation is 
required to maintain scleraxis levels.  
In addition to being an early tendon marker, scleraxis has also been shown to 
positively regulate tenomodulin expression.347 Tenomodulin, is a transmembrane 
glycoprotein found in tenocytes and its expression promotes tenocyte proliferation and 
tendon maturation.348  When compared to the tenocyte control, a similar level of 
expression is seen with the extract supplementation, while it increases significantly after 
14 days.  This correlates with the cellularity data which showed a significantly greater 
number of cells present in the construct with supplemented MSCs compared to the 
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tenocyte culture.  In addition, the histological images showed a much more tendon-like 
appearance with the supplemented group compared to the tenocyte group. 
 
5.5 Conclusions 
 It has been shown that tenocytic extract can positively affect tenocytic-like 
development of a MSC-seeded HUV construct.  By supplementing the seeding of the 
HUV with tenocytic extract, cellular proliferation increased, mechanical properties 
improved, more ECM was produced, and the gene expression of the MSCs followed a 
tenocytic differentiation progression after 14 days.  While other studies have utilized 
growth factors to chemically stimulate MSC differentiation, this is the first study that 
has utilized tenocytic extract along with mechanical stimulation to positively effect 
tenocytic development within a tissue-engineered tendon construct. 
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Chapter 6:  Increasing the Quality of a Modified Tissue-Engineered 
Tendon Construct by Long Term Culture 
  
6.1 Introduction 
 One of the issues experienced within tissue engineering is mass transport within 
the artificial tissue.  In the body, vasculature is responsible for delivering nutrient and 
oxygen to cells living within about 100 m of the vasculature.291    Unless vasculature is 
incorporated in the initial scaffold, the cells must rely on mass transport through the 
exterior of the scaffold to where the cells are located.  Some bioreactors can introduce 
flow through the scaffold increasing transport rates utilizing convection, such as the 
flow perfusion bioreactor.223  In contrast, the tendon tissue bioreactor utilized in these 
studies incorporates the flow outside of the tissue construct. 
Previous studies with the HUV/MSC construct have shown promise with the 
HUV scaffold for tendon tissue engineering.178–180  After 2 weeks, the tensile strength 
increased to 4 MPa, a 300% increase compared to static controls, a 20 fold increase in 
cell number and increased tissue formation and remodeling.180  However, since the 
HUV is cylindrical and the cells were seeded in the interior of the scaffold, the major 
method of nutrient transport to the cells and waste transport away from the cells was 
diffusion to and from the circulation media external to the HUV.  It was thought that as 
new tissue was deposited and integrated into the scaffold by the cells, diffusion rates 
dropped due to a reduction in effective porosity, deteriorating the construct.  This 
limited the amount of cells supported by the scaffold and the amount of time the 
construct would be cultured.180  It was found that after 2 weeks of culture within the 
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HUV, although construct properties were still improved, cells began to undergo 
apoptosis, lysed cell bodies were found, and ECM was degraded, indicating that 2 
weeks was the longest viable culture time for a closed HUV construct with cells seeded 
in the interior.180 
This study aimed to solve these issues.  During bioreactor culture, the HUV is 
altered by cutting the scaffold lengthwise and opening it up into a flat sheet, where the 
seeded cells can be exposed to circulating media. It is hypothesized that by seeding the 
cells on the Wharton’s jelly side of the scaffold, the efficiency of the cell seeding will 
be greater than on the luminal side of the HUV.  It is also hypothesized that the 
diffusion length is decreased and eliminated at the scaffold surface, allowing for longer 
culture times (up to 4 weeks) and therefore superior construct properties compared to 
the previous methods.  Finally, by culturing the construct as a closed cylinder for up to 
14 days and then opened into a flat sheet, the cells seeded in the interior will be 
protected from the undesirable fluid shear stress stimulation which can influence MSCs 
towards osteogenesis.349 
 
6.2 Methods 
6.2.1 Scaffold Preparation 
 Human umbilical cords were obtained from Norman Regional Hospital 
(Norman, OK).  The umbilical cords were then cleaned and prepared according to 
previous methods to extract the HUV.179  Briefly, the umbilical cord was mounted onto 
a stainless steel mandrel and frozen at -80°C for at least one day.  The umbilical cord 
was then removed from the vein using a computerized lathe.  The resulting HUV had a 
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wall thickness of 0.75 mm.  The cord was then either cut length wise if were to be 
cultured in an open state immediately or it was inverted and remained cylindrical if a 
closed bioreactor culture was to be used initially.  The cords were then decellularized 
and washed in a 1% sodium dodecyl sulfate (JT Baker, Center Valley, PA), ethanol, and 
0.2% peracetic acid washes (Sigma Aldrich, St. Louis, MO).  The resulting scaffold was 
then pH adjusted in phosphate buffered saline to 7.2-7.4.  Scaffolds were kept for a 
maximum of 5 days at 4°C prior to use. 
 
6.2.2 MSC and Tenocyte Isolation 
 Both MSCs and tenocytes were extract utilizing similar techniques as in 
chapters 4 and 5.   
 
6.2.3 Tenocytic Extract Preparation  
 Extract was prepared as in chapter 5.  A Bradford Assay indicated that there was 
46.1 ± 3.7 mg/mL of protein in the extract. 
 
6.2.4 Experimental Design 
 MSC-seeded HUV constructs were cultured in a custom made bioreactor for 
periods of up to 4 weeks as pictured in figure 6.1.  Two types of culture were 
performed:  either a flat, open construct from the beginning or an initial culture with the 
cylindrical form the HUV as had been done previously.  If the construct was cultured 
initially in the cylindrical from, after 2 weeks, the construct was then opened up into a 
flat sheet and cultured for an additional 2 weeks, for a total of 4 weeks time. 
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 To determine the best surface to seed the MSCs onto the flat sheet, a seeding 
efficiency test was performed.  1.8 million cells were seeded on either the luminal or 
Wharton’s jelly surface of the HUV in a 250 L suspension of a-MEM with 40 mg/mL 
extract concentration.  Both surfaces can be seen in figure 1.  The suspension was 
placed evenly throughout the scaffold and then cultured for 4 hours, 1 day, or 7 days to 
determine efficiency and initial growth patterns.  The surface determined to be more 
conducive for cell growth was used for all further experiments. 
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Figure 6.1:  (a) Luminal surface used for seeding efficiency test.  (b)  Wharton’s 
jelly surface used for seeding efficiency test. 
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For an initially closed bioreactor culture, established procedures were followed.  
MSCs were suspended in a mixture of 2 mg/mL collagen type I and tenocytic extract 
resulting in an extract concentration of 16.8 mg/mL and 3 million cells/mL.  0.6 mL of 
the solution was then injected into the middle of the HUV and sealed with stainless steel 
adapters.  The collagen hydrogel was allowed to gelatinize for 2 hours at 37°C.  
Afterwards, the constructs were placed into the bioreactor.  After 2 weeks, the 
constructs were removed and cut open lengthwise to result in a flat sheet.  Closed 
culture was not continued after 2 weeks due to previous studies that showed ECM 
degradation and cell death in the construct after 2 weeks of closed culture.180  Stainless 
steel clips were then used to attach the construct into the bioreactor.  Figure 6.2 shows a 
comparison of the flat and cylindrical constructs and their placement in the bioreactor.  
These constructs were then cultured for 1 or 2 additional weeks for a total of up to 4 
weeks. Every day during culture, the construct was cyclically stretched for 0.5 
hours/day at 0.5 cycles/min at a 2% strain.  After the end of the culture period, 
constructs were removed and prepared for further analysis.   
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Figure 6.2: (a) Cylindrical, closed configuration of HUV for initial bioreactor 
culture.  (b)  Open flat configuration of the HUV for extended culturing.  (c)  
Bioreactor culture of the cylindrical constructs.  (d)  Bioreactor culture of the flat 
constructs. 
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To seed initially flat constructs for bioreactor culture, 1.8 million cells were 
suspended in 250 L of -MEM supplemented with 40 mg/mL of tenocytic extract.  
These constructs were then cultured for 1 day in a petri dish prior to bioreactor culture 
to allow for sufficient MSC integration onto the scaffold.  This was done due to the 
direct exposure to circulating media and the potential to detach cells.  After the static 
period, the constructs were placed in the bioreactor with stainless steel clips as 
described prior.  The culture was then performed for up to 4 weeks with the same 
mechanical stimulation as was performed with the initially closed cultures.   
As a control, static cultures were performed on the flat constructs in a petri dish.  
These were prepared exactly the same as the experimental cultures.  However, they 
remained in the petri dish during the entire 4 weeks and were not subjected to 
stimulation. 
For all bioreactor cultures,  -MEM without extract was circulated at 1 mL/min 
and replaced every 3 days.  The cultures were performed at 37°C and 5% CO2. 
 
6.2.5 Cellularity  
 Cellularity analysis was done as described in chapter 4. 
 For seeding efficiency tests, the same protocol was performed, however, the 
entire scaffold was digested analyzed instead of strips or ringlets. 
 
6.2.6 Mechanical Testing 
 Mechanical analysis was done as described in chapter 4. 
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6.2.7 Histology 
 Histology was performed in the same manner as chapter 4. 
 
6.2.8 Gene Expression 
 RNA and DNA were isolated and produced utilizing the same methods as 
chapter 4.   The tendon genes investigated for this study were: collagen type I, collagen 
type III, biglcyan, elastin, COMP, scleraxis, and tenomodulin. These primers were 
identical to chapter 4.  In addition, two osteogenic markers were investigated, Sp7 
(Osterix) (Forward 5’ to 3’: CTTTCCCCACTCATTTCCTG Backwards: 5’ to 3’: 
CTAGGCAGGCAGTCAGAAG) and osteocalcin (Forward 5’ to 3’: 
AAGCCCAGCGACTCTGAGTC Backwards: 5’ to 3’: 
GCTCCAAGTCCATTGTTGAGG).310,350  These primers were the same sequences as 
chapter 4.  RT-PCR and preparation was also done the same as in chapter 4.  The 
analysis was also done utilizing the 2-Ct method with static MSCs as a control.311 
 
6.2.9 Statistics 
 All analysis was performed utilizing ANOVA and Bonferroni Post tests for 
significance between individual groups.  A p < 0.05 was used for significance.  Sample 
sizes of 3 or more was used for each analysis.  All data was reported as as mean 
standard deviation.  
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6.3 Results 
6.3.1 Seeding Efficiency 
 The seeding of the luminal side of the scaffold resulted in lower cell numbers 
compared to seeding on the Wharton’s jelly at all time points as seen in figure 6.3.  
After 4 hours, the luminal seeded scaffold had 0.5 ± 0.04 million cells while the 
Wharton’s jelly seeded scaffold has 1.2 ± 0.3 million cells, a significant difference of 
167%.  At 7 days, a similar difference existed, with the lumen having 0.9 ± 0.1 million 
cells and the Wharton’s jelly scaffold had 2.1 ± 0.4 million cells, another significant 
difference of 133%.  Both the luminal and Wharton’s jelly groups showed significant 
increases from initial seeding to 7 days with 95% and 75% increases respectively.   
 
Figure 6.3:  Cellularity of scaffolds used for seeding efficiency tests.  * indicates p < 
0.05 for specified groups. Data represented as mean standard deviation. A 
sample size of n ≥ 3 was used. 
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6.3.2 Cellularity 
 Bioreactor culture of the initially flat scaffold demonstrated significant increases 
of cells from week to week, shown in figure 6.4.  At initial bioreactor culture of the flat 
construct, there was 1.7 ± 0.1 million cells as reported for the seeding efficiency.  After 
4 weeks of culture, there was 26.0 ± 6.4 million cells, a 15.3 fold increase in cells.  
Continuous open culture also possessed a significant increase in the amount of cells 
compared to the initially closed culture, with 63%, 71%, 92%, and 72% increase at 1, 2, 
3 and 4 weeks respectively. The initially closed culture did have significant increases in 
cell number after 14 days, increasing to 3.87 ± 0.5 million cells.  After 28 days, the 
initially closed then opened culture had reached a maximum cell number of 15.1 ± 3.05 
million cells. 
Static controls did see a significant increase in cell number from the initial 
seeding efficiency cellularity of 1.2 ± 0.3 to the 7 day culture, which had 2.1 ± 0.4 
million cells.  However, after 7 days there was no more significant increase in the 
number of cells.  After 28 days, the cellular concentration of the scaffold had reached 
3.2 ± 0.5 million cells.  At each time point, the application of mechanical stimulation, 
either initially closed or open, increased the number of cells significantly compared to 
the static control.  After 4 weeks of culture, the initially closed scaffold had 371% more 
cells compared to the static control while the initially open scaffold had 706% more. 
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Figure 6.4: Cellularity of experimental constructs cultured in the bioreactor and 
the static controls. * indicates p < 0.05 between experimental and control groups. 
Letters indicate p < 0.05 between various time points in the same experimental 
group. Data represented as mean standard deviation. A sample size of n ≥ 3 was 
used. 
 
6.3.3 Histology 
 Histological sections of the construct show the amount and alignment of the 
ECM present in the constructs.  Figure 6.5 shows the static control throughout 28 days 
of culture along with the original decellularized construct.  ECM content increases 
throughout the 28 days, however, up until 14 days the fibrils are irregular, thin, and 
disorganized (figures 6.5b and 6.5c), similar to the decellularized construct (figure 
6.5a).  At 21 days, the ECM becomes thicker, but still disorganized and at day 28, some 
fibrils are straight while other portions of the construct has irregular matrix still. Table 
6-1 quantifies that the fibril alignment does increase somewhat through 28 days. 
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Figure 6.5:  Histological sections of statically cultured flat constructs.  
Magnification is 10x and scale bar is 200 m. (a) Decellularized scaffold, (b) 1 
week, (c) 2 weeks, (d) 3 weeks, (e) 4 weeks. 
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 The addition of mechanical stimulation increases the alignment of fibrils of the 
ECM as seen in both the initially open scaffold (figure 6.6) and the initially closed then 
opened scaffold (figure 6.7).  With the initially open scaffold, ECM deposition 
increases throughout the 28 days, similar to the static controls.  However, even after 7 
days, ECM fibrils are fuller and aligned in parallel, which was not the case with the 
static controls.  Similar trends were seen with the initially closed scaffold.  ECM 
amounts appear to be similar through 21 days.  At 28 days (figure 6.7d), the tissue 
appears to resemble dense connective tissue with parallel fibrils.  This is in comparison 
to the 28 day construct that was initially open (figure 6.6d), it also has similar amounts 
of ECM, however, it is less aligned in the direction of stretching, as also indicated in 
tables 6-2 and 6-3. 
 Cross sections of the HUV shown in figure 6.8 show cellular penetration within 
the scaffold.  The initially open scaffolds showed less penetration (figures 6.8a-e) than 
the initially closed then opened scaffolds (figures 6.8f-j).  Cells remained at the surface 
or within 40% of the surface depth through 28 days on the initially open scaffolds (table 
6-4).  After 28 days, cells did penetrate more, reaching at least half the depth of the 
scaffold.  In contrast, the initially closed culture demonstrated continuing penetration 
from the start of the culture through 14 days, while the scaffold was still closed (figures 
6.8f-h).  After opening the scaffold up for additional culture, cells remained throughout 
the scaffold (figures 6.8i and 6.8j). 
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Figure 6.6:  Histological sections of always open constructs cultured in the 
bioreactor.  Magnification is 10x and scale bar is 200 m. (a) 1 week, (b) 2 weeks, 
(c) 3 weeks, (d) 4 weeks. 
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Figure 6.7:  Histological sections of constructs that were closed for 2 weeks and 
then open for 2 weeks cultured in the bioreactor.  Magnification is 10x and scale 
bar is 200 m. (a) 1 week, (b) 2 weeks, (c) 3 weeks, (d) 4 weeks. 
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Figure 6.8:  Cross sections of  HUV/MSC constructs.  Magnification is 4x and scale 
bar is 500 m.  a) Seeded initially open culture, b) 1 week initially open culture, c) 
2 weeks initially open culture, d) 3 weeks initially open culture, e) 4 weeks initially 
open culture f) Seeded initially closed culture.  Arrows indicate cells within the 
scaffold. 
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Figure 6.9: Continued cross sections of  HUV/MSC constructs.  Magnification is 4x 
and scale bar is 500 m. g) 1 week initially closed culture, h) 2 weeks initially 
closed culture, i) 3 weeks initially closed culture, j) 4 weeks initially closed culture.  
Arrows indicate cells within the scaffold. 
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Mean Std. Dev. 
0 Days 0.15 0.04 
7 Days 0.14 0.05 
14 Days 0.08 0.03 
21 Days 0.23 0.06 
28 Days 0.35 0.09 
Table 6-1: Anisotropy values for the closed open group based on lateral 
histological sections. 
 
 
Mean Std. Dev. 
7 Days 0.29 0.06 
14 Days 0.40 0.01 
21 Days 0.26 0.02 
28 Days 0.09 0.04 
Table 6-2: Anisotropy values for the closed open group based on lateral 
histological sections. 
 
 
Mean Std. Dev. 
7 Days 0.47 0.03 
14 Days 0.52 0.01 
21 Days 0.47 0.06 
28 Days 0.40 0.08 
Table 6-3:  Anisotropy values for the closed open group based on lateral 
histological sections. 
 
 
Always Open Closed/Open 
 
Mean Std. Dev. Mean Std. Dev. 
7 Days 18% 5% 42% 6% 
14 Days 16% 7% 72% 7% 
21 Days 39% 7% 71% 7% 
28 Days 23% 4% 77% 10% 
Table 6-4:  Maximum cell penetration determined by histological cross sections of 
the always open and closed/open experimental groups. 
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6.3.4 Mechanical Properties 
 Figure 6.9 shows that the addition of cells significantly increased the ultimate 
tensile strength of the scaffold compared to the decellularized scaffold, which had an 
initial ultimate tensile strength of 1.0 ± 0.4 MPa.  This occurred in the static cultures at 
day 14 and both mechanically stimulated cultures after 7 days of culture.  However, the 
static cultures did not have significant improvements after 14 days of culture.  After 14 
days, the ultimate tensile strength was 2.5 ± 0.6 MPa and after 28 days it was 2.9 ± 1.1 
MPa.  The addition of mechanical stimulation via the bioreactor did increase the 
ultimate tensile strength after 7 days of both the initially open construct (3.2 ± 0.7 MPa) 
and the initially closed construct (1.7 ± 0.4 MPa). However, no other significant gains 
were seen even after 28 days for the always open construct which had an ultimate 
tensile strength of 3.7 ± 0.7 MPa.  At 28 days there was a significant difference between 
initially culturing with a flat or cylindrical configuration, as the closed then opened 
culture had an ultimate tensile strength of 5.6 ± 0.7 MPa, a 50% increase compared to 
the initially open construct. 
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Figure 6.10: Ultimate tensile strength of experimental constructs and static 
controls.  * indicates p < 0.05 between various experimental and control groups.  
Letters indicate p < 0.05 between various time points in the same experimental 
group. Data represented as mean standard deviation. A sample size of n ≥ 3 was 
used. 
 
 Elastic modulus results are shown in figure 6.10.  Static culture of the constructs 
had a significant differences in the elastic modulus after 14 days compared to the 
decellularized scaffold: 4.1 ± 0.1 MPa vs 0.7 ± 0.3 MPa, a 5.9 fold increase.  However 
there were no other significant differences for the static cultures.  For the initially open 
construct, mechanical stimulation increased the elastic modulus after only 7 days of 
culture compared to the decellularized construct with an elastic modulus of 6.4 ± 3.6 
MPa, an 814% increase.  The elastic modulus thereafter did not show any significant 
increases.  The initially closed construct only significantly increased its elastic modulus 
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after 14 days to 3.2 ± 2.2 MPa. However, it had the highest elastic modulus after 28 
days, 9.55 ± 3.92 MPa, a 338% increase from the beginning of the bioreactor culture. 
 
Figure 6.11: Elastic modulus of experimental constructs and static controls.  * 
indicates p < 0.05 between various experimental and control groups.  Letters 
indicate p < 0.05 between various time points in the same experimental group. 
Data represented as mean standard deviation. A sample size of n ≥ 3 was used. 
 
6.3.5 Gene Expression 
 Figure 6.11 demonstrates that the initially closed then opened construct provided 
many significant responses in gene expression.  This configuration had a significant 
increase in collagen type I gene expression compared to the static control from 7 to 14 
days:  
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Figure 6.12:  Gene expression for initially closed constructs.  (a)  Tendon-related 
ECM molecules and (b) Tendon markers and osterix, an osteogenic marker. * 
indicates p < 0.05 between time points, # indicates p < 0.05 between the initially 
open and initially closed constructs. Data represented as mean standard 
deviation. A sample size of n ≥ 3 was used. 
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from 1.5 ± 0.3 to a 4.6 ± 0.8 fold increase in gene expression compared to the static 
control.  The expression then significantly decreased from 21 days (5.2 ± 0.8 fold) to 28 
days (2.7 ± 0.5 fold).  Collagen type III significantly increased from the first to fourth 
culture week, increasing from 0.4 ± 0.04 fold to 7.5 ± 0.6 fold.  Biglycan expression 
only increased between the first and second weeks of culture from 1.0 ± 0.1 fold to 5.6 
± 1.0 fold, an increase of 450%.  Elastin was mostly downregulated, with the exception 
of an increase after 14 days to a 1.2 ± 0.1 fold increase in expression. 
 Figure 6.11b presents the expression levels for several tendon markers and one 
osteogenic marker for the closed then opened.  COMP alternated upregulation and 
downregulation from 1 to 4 weeks, with a maximum expression after 21 days of 2.8 ± 
0.8 fold increase compared to the control.  Scleraxis expression was significantly 
increased after 14 days with a 3.4 ± 1.1 fold increase in expression levels.  It then 
decreased after 21 days to a 1.5 ± 0.7 fold increase compared to controls.  Tenomodulin 
only significantly increased after 28 days, with a 2.0 ± 0.3 fold increase.  Osterix and 
osteocalcin, showed no appreciable changes and was under expressed throughout. 
 The bioreactor cultures that were always open from the beginning also had 
significant changes in gene expression, however it was different time and amounts 
compared to the initially closed scaffold configuration.  These are presented in figures 
6.12a and 6.12b.  Collagen type I expression compared to the control increased until 
day 21, where it had a 7.0 ± 0.4 fold increase in expression compared to the static 
control.  However, it then decreased in levels to 2.3 ± 0.1 after 28 days.  Collagen type 
III demonstrated similar trends, however, it was not significantly increased from 7 to 14 
days.  However, it also  
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Figure 6.13:  Gene expression for initially open constructs.  (a)  Tendon-related 
ECM molecules and (b) Tendon markers and osterix, an osteogenic marker. * 
indicates p < 0.05 between time points, # indicates p < 0.05 between the initially 
open and initially closed constructs. Data represented as mean standard 
deviation. A sample size of n ≥ 3 was used. 
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reached a maximum after 21 days (4.9 ± 1.4 fold) and then decreased in levels after 28 
days (0.7 ± 0.3 fold).  This expression also indicated a downregulation compared to the 
static controls after 28 days.  Biglcyan possessed a significant increase in expression 
after 28 days, with a 3.2 ± 1.3 fold increase compared to the static control. Elastin was 
also relatively downregulated as was the case in the initially closed configurations, but 
did was upregulated after 28 days to a 1.3 ± 0.5 fold increase compared to the static 
control.  COMP continually decreased in expression levels through 21 days, initially 
being overexpressed at 7 days (2.1 ± 0.1) to becoming downregulated at 21 days (0.2 ± 
0.1). Scleraxis behaved similarly to biglycan in the open configuration, as it only 
significantly increased after 28 days to a 2.1 ± 0.9 fold increase compared to the static 
controls.  Tenomodulin remained downregulated throughout the culture times, even 
decreasing from 14 to 21 days: 1.0 ± 0.04 fold to 0.04 ± 0.04 fold respectively.  The 
largest difference in gene expression between the initially open and closed 
configurations was seen with the osterix gene.  As an always open flat sheet, expression 
was initially downregulated after 14 days (0.5 ± 0.2 fold), but then significantly 
increased in expression at 21 days and once again at 28 days, reaching its largest 
expression level of a 4.4 ± 0.6 fold increase. Osteocalcin also demonstrated a significant 
increase in expression resulting in upregulation of the gene, but only after 28 days of 
open culture, as it increased 296% from day 21 to a 1.9 ± 0.5 fold increase compared to 
the static control. 
 
 There were also some significant differences between the gene expressions for 
not only the culture time points, but also between the initially open and closed 
configurations.  After 1 week, there were no differences.  However, after 2 weeks, 
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biglycan (1268%), elastin (203%), and scleraxis (2990%) expressions were all higher 
for the closed configuration and COMP (707%) was lower.  After 3 weeks, collagen 
type I (33%) and osterix (382%) were lower for the closed configuration while biglycan 
(353%), COMP (1343%), and scleraxis (794%) were higher.  Finally, after 4 weeks of 
culture, collagen type III (975) and tenomodulin (74%) were higher while elastin 
(216%), scleraxis (336%), osterix (571%), and osteocalcin (202%) were lower. 
 
6.4 Discussion 
 Previous culturing of the HUV/MSC construct for tendon tissue engineering 
showed much promise.  However, the closed nature of the construct limited the length 
of time the construct could be cultured to two weeks due to nutrient transport limitations 
that caused cell death and ECM degradation.180  By opening up the construct, either 
initially or after two weeks of closed culture, longer culture times could be 
accomplished.  With the longer culture times, cellularity, mechanical properties, 
construct quality, and gene expression improved or changed compared to the shorter 
time points.  However, there were differences depending on when the cylindrical 
construct was opened up into a flat sheet.  The always open construct did show greater 
cell content, however, its gene expression and mechanical properties were poorer 
compared to the construct that was closed for 2 weeks and then opened into a flat sheet 
for 2 weeks in the bioreactor. 
 An initial seeding efficiency test was first performed to determine the best 
surface of the newly flat tendon for cell attachment. With previous HUV/MSC 
constructs, the HUV was always inverted so that any residual Wharton’s jelly tissue 
121 
would be on the inside of the scaffold where the cells were seeded.179,180   This was 
done to enhance initial cell attachment since the Wharton’s Jelly is a rougher surface 
than the luminal side as seen in figure 6.1.  It has been shown that increased roughness 
of the scaffold surface can positively influence MSC attachment and differentiation.351–
353  In addition, Wharton’s jelly has large amounts of glycosaminoglycans and 
proteoglycans such as hyaluronic acid and heparin and chondroitin derivatives that can 
assist with cell attachment and growth.318,354–357  In addition, a study coated the human 
umbilical artery with fibronectin to facilitate cell seeding.186  However, it was never 
initially tested with this specific construct that this was actually more beneficial, and 
with the addition of fluid shear, the seeding density experiment was performed to ensure 
the best cell attachment.  It was found that it was true that the Wharton’s jelly surface 
was more beneficial, as after both four hours and 7 days, there was significantly more 
cells on the Wharton’s jelly seeded surface than the luminal surface:  167% and 230% 
respectively. Therefore, for any further experiments, cells were always seeded on the 
Wharton’s jelly surface of the scaffold, whether it be initially a flat sheet or a closed 
cylinder. 
 When cultured in the bioreactor, cellularity continued to increase.  When 
initially cultured as a flat sheet, the cellularity significantly increased week over week, 
reaching a peak cellularity after 28 days of 26.0 ± 6.4 million cells.   The same was true 
for the construct that was initially cultured in cylindrical form and then opened, and 
after 4 weeks it had 15.1 ± 3.0 million cells.  In each case, the always open construct 
contained more cells than its closed then open counterpart.  This could be attributed to 
the extra initial exposure to fluid shear on the surface of the scaffold where the majority 
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of the cells resided in early time points.  It has been shown that fluid shear does 
positively influence cellular proliferation, and the cylindrical configuration shields the 
cells from this influence.358,359  In both experimental groups, the cells also experienced 
stimulation from the cyclical stretching of the bioreactor, which also has been shown to 
increased proliferation rates.179,180,360  This can be seen by comparing either bioreactor 
culture group to the appropriate static control.  Overall the static group saw no 
significant gains after 1 week in the petri dish. 
Previously, cylindrical constructs seeded with 1.8 million cells reached an 
ultimate tensile strength of 2.7 ± 0.8 MPa after 2 weeks of culture, the maximum culture 
time due to diffusional limitations for a closed construct.180  It was hypothesized that 
longer culture times should increase the ultimate tensile strength of the construct due to 
increased cellularity and ECM production and remodeling.  This turned out to be true, 
as both the always open or closed then open cultures both had improvements in the 
ultimate tensile strengths over the previously reported value after 4 weeks – 3.7 ± 0.7 
MPa for the initially and 5.6 ± 0.7 MPa for the initially closed group.  As seen in table 
1, this is similar to ultimate tensile strengths of certain rotator cuff tendons.  This 
difference between the two groups was also statistically significant.  In addition, the 
initially closed scaffold also saw significant increases between 3 weeks and 4 weeks 
culture time, where the initially flat scaffold did not.  When looking at the elastic 
modulus, there is a significant increase when cyclical stretching is applied to the 
construct in the bioreactor when compared to the decellularized scaffold.  Otherwise 
there is no strong correlation between being initially open or closed or increasing 
culture times. 
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The histological sections correlated to tensile strength data.  The static 
constructs throughout the time points had a disorganized extracellular matrix, which 
coincided with no significant increases in tensile strength throughout the culture until 
day 14, where there was more ECM present than the day 0 or day 7 cultures to provide 
more structural integrity.  Comparatively, dynamically cultured constructs, both the 
initially open and closed, showed ECM alignment in the direction of stretching after 7 
days and also had significant increases in their ultimate tensile strength compared to the 
decellularized construct.  However, the always open construct had shorter, thicker 
fibrils up until day 28, while the initially closed then open construct had longer, more 
aligned fibers.  At day 28, both bioreactor cultures possessed an almost continuous 
matrix.  However, a closer look shows that there appears to be a more fibrillar 
appearance with the initially closed construct compared to the initially open construct, 
which appears more discontinuous and wavy.  The fibrillar alignment in the 
longitudinal direction provided more tensile strength in the initially closed construct 
than the initially open construct, which was not as organized, resulting in significant 
increases in the ultimate tensile strength at day 28. 
In terms of cellular penetration, the initially open cultures maintained most of 
the cell population near or at the surface until day 28 where penetration occurred further 
into the scaffold.  This is in contrast to the initially closed scaffold, which promoted 
cellular penetration at the beginning of culture, resulting in cellular penetration through 
nearly the entire scaffold at day 14. These cells remained distributed throughout the 
scaffold even after opening the scaffold up into a flat sheet.  This penetration difference 
could be due to chemotactic migration of the MSCs which can be initiated by FBS 
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supplemented media.361  In the initially open scaffold, surface cells are exposed to 
circulating media directly and an immediate source of nutrients and oxygen.  While in 
the initially closed scaffold, the cells are in the interior of the scaffold isolated from 
circulating media on the outside of the scaffold.  Therefore, the cell would migrate 
towards the exterior of the scaffold where nutrients are in higher concentration. 
The gene expression profiles of the groups indicate that always open scaffold 
may delay and even hinder tenocytic development in favor for some osteogenic 
development.  This could be due to the immediate exposure of the MSCs which are 
mainly at the surface of the scaffold to fluid shear stresses, which have been shown to 
induce osteogenic differentiation even without soluble cues such as dexamethasone or 
BMP-2.349  This pathway could provide competition with the tenocytic pathway which 
is favored by the cyclical stretching provided by the bioreactor.235 For example, 
scleraxis, which is an early marker of tendon development is significantly more 
expressed in the 14 and 21 day culture time points in the initially cylindrical construct 
compared to the flat construct.362  Furthermore, scleraxis is downregulated during those 
two time points for the open construct, and isn’t significantly upregulated until day 28, 
where it is actually significantly greater than the closed construct.  However, scleraxis is 
an early tendon marker and regulates tenomodulin which is a late term tendon marker.62  
Compared to the initially closed construct, in which tenomodulin is significantly 
upregulated after 4 weeks when compared to earlier time points or the open construct, 
indicating a more mature tendon phenotype of the cells after 4 weeks.   
Another possible explanation for the initially closed construct having more 
positive tendon-related gene expression could be due to the tenocytic extract and how it 
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was delivered.  As a closed cylinder, the extract is placed within the sealed construct 
along with the cells, protecting and containing it.  When it supplements the seeding of 
the always open scaffold, there is a potential for some loss of the extract as it is on the 
surface of the scaffold along with the cells.  This would provide the initially closed 
scaffold with a potentially stronger exposure initially to the tenocytic extract that was 
shown in chapter 5 to have beneficial tenocytic differentiation capacities. 
In addition to tendon markers, osterix and osteocalcin were investigated as 
osteoblastic differentiation markers. Osterix is a transcription factor required for 
osteogenic differentiation and osteocalcin is a protein secreted mainly by 
osteoblasts.363,364  When looking at this marker, there is no increasing trend or signal 
from the initially closed then opened construct.  For the always open group, the cells 
had been experiencing fluid shear from the start, and after enough time such as 3 and 4 
weeks, there is significant upregulation of osterix compared to earlier time points and 
the initially cylindrical construct.  Osteocalcin behaves similarly after 4 weeks of 
culture in the always open construct. Whereas the initially closed then open scaffold 
possesses cells that are penetrated into the scaffold by the time the scaffold is opened 
up, protecting them from the fluid shear stimulus (figure 6.8). This indicates that the 
additional exposure to fluid shear by the initially open construct may actually promote 
osteogenic differentiation of some cells, even with the presence of the cyclical 
stimulation of the bioreactor.   
In terms of collagen content, both groups did show increasing amounts of 
collagen up to 21 days. However, the always open configuration actually had a larger 
expression of collagen type I after 3 weeks.  The same trends hold true for collagen type 
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III, however, at 28 days, the closed then open configuration significantly increases its 
expression, while the open configuration actually decreases its expression.  This could 
be due to the initially flat construct possibly preferring an osteoblastic lineage.  
Collagen type III is often found in developing tendons and also comprises about 5% of 
the total collagen content in mature tendons along with collagen type V.43,44  
Comparatively, bone development begins with mostly collagen type I and small 
amounts of collagen type III and which provides the base for mineralization.365,366 This 
could be the reason they are upregulated significantly at day 21 and then decreased in 
expression at day 28, as the osteogenic marker, osterix was also upregulated starting at 
day 21, indicating osteoblastic tendencies.  Meanwhile, since mature tendons still are 
comprised of collagen type III in small amounts, its expression remains upregulated.  
 Other genes such as COMP, biglycan, and elastin were also investigated.  
Biglycan contributes to the musculoskeletal system development and is also present in 
the HUV, although in smaller amounts compared to other proteoglycans.318,367  It is 
expressed in high amounts in the developing tendon and responsible for ECM 
organization.368,369 By differentiating into musculoskeletal lineages, whether it is 
osteogenic or tenocytic, the cells appear to be producing more biglcyan by increasing 
the expression the biglcyan gene to make up whatever deficit may be present.  This 
expression occurred earlier with the cylindrical construct (2 and 3 weeks) compared to 
the open construct (4 weeks) further indicating construct development may be delayed 
with the always open configuration.  This is also true with the elastin expression, which 
is another small, but critical component for tendon function.370  The upregulation of this 
gene occurs at 2 weeks for the closed system while it is expressed in high amounts after 
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4 weeks for the always open construct.  COMP, a glycoprotein serves many purposes 
and is present in abundance in tendons.371  It can help in ECM production by catalyzing 
fibrillogenesis of collagen fibers and it is also thought to bind and present BMP-2 in 
bone tissue.344,372  However, for the always open construct, the highest expression of 
COMP is present at 7 days.  The cells may be producing COMP for fibrillogenesis at 
this point, and as they are exposed to fluid shear and tending towards osteogenesis, the 
existing COMP may also possibly be used as a presenter molecule.   
 
6.5 Conclusions 
 This work has shown that by opening the HUV/MSC construct into a flat sheet, 
long term bioreactor culturing for tendon tissue engineering can be accomplished.  
Along with this increased culture time, construct properties such as cellularity, tensile 
strength, and ECM quality and quantity are shown to be increased.  However, by 
opening up the construct initially, the immediate influence from fluid shear from 
circulating media caused a delay in tenogenic development and possible osteogenic 
differentiation of the MSCs present on the scaffold, even with cyclical stretching.  This 
was prevented by allowing the construct to be cultured in a closed cylindrical shape 
initially for 2 weeks to protect the cells from the osteoblastic influence of fluid shear.  
Another two weeks of open culture removed any diffusional limitations that had 
previously occurred within the closed scaffold for long term culture.  This 4 weeks of 
increased culture time resulted in a superior construct compared to previous work that 
had only cultured the construct for 2 weeks.  The increased mechanical and ECM 
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properties cultured in vitro could allow for faster and better integration if the construct 
were used as a graft for tendon supplementation in the injury recovery process. 
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Chapter 7:  Conclusions and Future Directions 
7.1 Conclusions 
The studies discussed previously built upon the previous studies of the 
HUV/MSC construct as a viable option for tendon tissue engineering.  Ideally, these 
studies have pushed the HUV/MSC construct towards a more viable path as a graft 
alternative in surgical treatment of tendon injuries. 
The first study investigated how altering the duration and frequency of 
mechanical stimulation (previously done at 1 cycle/min and 1 hour/day) at 2% strain.  It 
was found that long duration and faster frequencies did not increase cellular 
proliferation at 7 days, while the slower frequencies and shorter durations did compared 
to the static control.  In addition, ECM amounts and alignment directly correlated the 
groups that had significant increases in cell number.  When investigating the levels of 
tendon related genes, it was found that the MSCs expressed high levels of biglcyan and 
low levels of elastin, which are found in low and high amounts respectively in the 
HUV, indicating a remodeling by the MSCs into a more tendon-like construct.  
Furthermore, differentiation appeared to begin after 7 days, with most stimulations 
upregulating some of the tendon markers, while downregulating the non-tendon 
markers, with the exception of the 1 hour/day and 1 cycle/min stimulation, which also 
increased non-tendon markers.  Overall, shorter durations and slower frequencies such 
as 0.5 hours/day and 0.5 cycles/min were most beneficial at least in early culture times 
of the HUV/MSC construct.  
The second study was concerned about supplementing the altered mechanical 
stimulation with chemical stimulation through the use of tenocytic extract, the 
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biochemical factors and genetic material released through lysing of mature tenocytes.  
When this was supplemented during seeding of the HUV with MSCs, the properties of 
the construct improved, even more so when combined with mechanical stimulation, 
providing a synergistic effect.  Tensile strengths increased by 33% compared to non-
supplemented groups, along with an increase in cell proliferation and ECM production.  
Gene expression indicated tenocytic differentiation was delayed slightly until after two 
weeks, however, the overall construct was greatly improved compared to not 
supplementing with extract 
Finally the third study investigated how long term culture would affect the 
construct.  Prior to this study, the original cylindrical HUV was limited to 2 weeks 
culture time in the bioreactor due to mass transport limitations.  By opening up the 
HUV into a flat sheet and exposing it to circulating media, culture times were increased 
to four weeks.  Opening of the construct at the beginning of the culture hindered 
tendon-like development of the construct, even upregulating osteogenic genes in the 
MSCs. However, by culturing the construct as a cylinder initially and then opening it 
after 2 weeks of culture, development improved.  After 4 weeks of culture, the ultimate 
tensile strength had reached 5.6 ± 0.7 MPa and gene expression results indicated the 
MSCs committed towards a tenocytic lineage after 2 weeks and maintained levels 
through the 4 weeks of culture.   
Overall, these studies built upon and improved the HUV construct.  The now 4 
week culture time showed increases in ECM production and gene expression compared 
to the previous studies.  In addition, the ultimate tensile strength of the construct 
increased by 36.6% from 4.1 ± 0.5 in previous studies to MPa 5.6 ± 0.7 MPa.180  This 
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tensile strength is approaching some of the physiological levels of some of the weaker 
tendons in the body such as the flexor tendon and rotator cuff.   Therefore, the 
HUV/MSC construct has a promising future with further improvements as a potential 
tissue-engineered tendon graft. 
 
7.2 Future Directions 
7.2.1  Long-term Mechanical Stimulation Variables 
In this study, chapter 4 investigated the frequency and duration of mechanical 
stimulation.  However, this was only for a 7 day culture period.  It found that a slower 
frequency and shorter duration was beneficial at earlier time points.  However, other 
studies have found that different that higher frequencies and durations on other types of 
tendon tissue engineering constructs have also been beneficial, along with higher 
strains. 
As the HUV/MSC construct matures, it is possible that different stimulation 
regimes may prove more beneficial than what was most beneficial at early time points. 
Since the construct requires more than 1 week of culture to develop sufficient tissue 
properties for in vivo use, it is pertinent to investigate whether different mechanical 
stimulation parameters may improve upon existing long term results or hasten the 
achievement of these results.  This could include investigating a wider range of 
durations and frequencies investigated in chapter 4 or also changing the amount of 
strain provided by the bioreactor, which was not changed in chapter 4.   
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Furthermore, strain rates were not varied in these studies.  It would be beneficial 
to see if changing the strain rates at early time points and also later time points (when 
the ECM has matured and improved) may impact construct development. 
 
7.2.2 Supplementation with Growth Factors and Extract Improvement 
The tenocytic extract has shown to significantly increase the properties of the 
HUV/MSC construct.  However, there are three potential issues with this technique.   
First, the mature tenocyte most likely does not provide all of the signaling to 
developing tendons in terms of ECM deposition, stem cell differentiation, and 
vascularization.  Vascularization is absolutely necessary at some point during tissue 
maturation, without it, when in the body, transport in the interior of the tissue will 
eventually be limited without adequate blood flow.  VEGF supplementation either at the 
end of in vitro culture or prior to implantation could potentially initiate 
neovascularization when the construct is placed into the body.  This is only one 
example that specific growth factor supplementation may provide that the extract 
cannot.   
Second, the exact composition of the extract is not known.  A better 
understanding of the composition of the extract could be beneficial.  The extract can 
then be supplemented further with missing growth factors to further enhance construct 
development. 
Finally, the life of this extract during initial supplementation is short lived.  To 
circumvent this, two options present themselves.  The extract could be encapsulated 
prior to placing in the HUV to control release rates and protect the extract.  Second, 
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when the construct is opened up in bioreactor culture, more extract or growth factors 
could be placed in the circulating media to maintain soluble factor levels.  This may 
further improve construct properties. As it is now implemented, only the early culture is 
exposed to the biochemical cues, although as it is seen it does positively affect future 
development. 
 
7.2.3 Engineering of Bone-Tendon Enthesis 
As discussed in the introductory sections, the tendon consists of three major 
zones:  the main tendon midsubstance, the bone-tendon junction, and the muscle-tendon 
junction.  To facilitate greater acceptance of the graft and more complete healing, the 
ideal tendon construct would mimic this architecture. 
Of these, the tendon-bone enthesis is the most complex structure.  It consists of 
transition zones from tendon to fibrocartilage to bone.  It is also the location of many 
tendon repair failures after surgery due to a lack of quality in the enthesis 
development.373  To facilitate stronger attachment, a fibrocartilage end of the construct 
should be developed.  If the construct was attached directly to the bone where a zonal 
enthesis is normally present, mechanical stability could be hampered initially or 
development of the enthesis could be poor compared to a natural enthesis.  This could 
be done utilizing gene transfection of the cells on one end of the construct or a hydrogel 
with cartilage related growth factors or chondrocytes attached to the end of the scaffold.  
Gene transfection has been done in MSCs in prior studies to influence chondrocyte 
development.374,375  Furthermore, it has been shown that uniaxial stretching is beneficial 
in fibrocartilage formation from MSCs differentiated into chondrocytes, creating a 
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symbiotic relationship with the cyclical stretching already present within the bioreactor. 
This fibrocartilage zone could then be further developed by adding osteogenic stimuli to 
promote osteogenesis in at the surface to further mimic the enthesis of the tendon. 
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